Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lannett (LCIN) : 0.149 - 35.22%
today: 149 - 0.285
52w: 0.149 – 3.72
mktcap: 1.6 million
https://www.findacode.com/ndc/labelers/Lannett_Company%2C_Inc.
Shares Outstanding 10.77M
Float 8.39M
Total Cash (mrq) 55.85M
Total Debt (mrq) 635.37M
Results of Insulin Study
The pivotal clinical trial of biosimilar insulin glargine demonstrated positive results, in line with prior expectations. The Company is co-developing this product with its strategic alliance partners within the HEC Group of companies (HEC). The single center, single-dose, double-blind, randomized, two-period, two-treatment, two-sequence, crossover study was designed to demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) similarity between Lannett/HECs biosimilar insulin glargine and US-Lantus® using the euglycemic clamp technique in healthy male adult volunteers. The study met all of its primary and secondary endpoints and no serious adverse events were reported. The data from the pivotal trial of the Company's biosimilar insulin glargine indicate that its insulin glargine is biosimilar to the reference product.
"We are pleased with the results of this crucial clinical trial of biosimilar insulin glargine," said Tim Crew, chief executive officer of Lannett. "We remain confident that biosimilar insulin glargine represents a significant commercial opportunity, and our team is diligently focused on advancing this product."
Lannett is moving forward expeditiously to complete the Biologics License Application, with the goal of submitting the application to the FDA within the next several months. Prior to filing, there are additional meaningful activities to complete, including a device differentiation study, which will run in April, and more comparability work showing HEC's insulin glargine is biosimilar to US sourced Lantus. Lannett also anticipates engaging with the FDA in a pre-submission meeting. There are significant steps necessary for the Company to receive FDA approval to effectively commercialize this product, and there is no guarantee that the Company will be successful in this regard.
The Company continues to assess the potential impacts of recent developments in the insulin market, including announcements by manufacturers related to lowering the price of insulin for patients, especially list prices, and enhancing market transparency. Lannett welcomes these initiatives to help drive greater access to this critical medicine and believes these changes dovetail with the Company's promising go-to-market approach.
Q2 Business and Financial Highlights:
• Net Sales were $80.9 Million
• Gross Margin was 18%, Adjusted Gross Margin was 19%
• Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters
• $19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31st
Pipeline Updates:
• Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023
• Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current Year
• Executed Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin Products Upon Approval
• Generic FLOVENT® DISKUS® ANDA Filing Anticipated by Mid Year
Apr 24, 2023 0.2300 0.2850 0.2094 0.2850 0.2850 40,646
Apr 21, 2023 0.3500 0.3500 0.2300 0.2300 0.2300 668,300
Apr 20, 2023 0.6600 0.7000 0.2500 0.3330 0.3330 1,167,800
Apr 19, 2023 0.6500 0.7196 0.6501 0.6855 0.6855 280,660
Apr 18, 2023 0.6530 0.6829 0.6530 0.6600 0.6600 30,585
Apr 17, 2023 0.7000 0.7000 0.6525 0.6525 0.6525 39,745
Apr 14, 2023 0.6400 0.7200 0.6375 0.6900 0.6900 129,657
Apr 13, 2023 0.6400 0.6960 0.6400 0.6700 0.6700 60,850
Apr 12, 2023 0.7600 0.7700 0.6600 0.6620 0.6620 126,490
Apr 11, 2023 0.9400 0.9478 0.7200 0.7221 0.7221 185,385
Apr 10, 2023 0.9750 0.9800 0.9067 0.9179 0.9179 30,979
Apr 06, 2023 0.9400 0.9500 0.9100 0.9205 0.9205 72,475
Apr 05, 2023 0.9800 0.9975 0.9300 0.9539 0.9539 312,304
Apr 04, 2023 1.8500 1.8500 0.8600 0.9700 0.9700 982,984
Apr 03, 2023 1.6800 1.8900 1.6800 1.8700 1.8700 25,574
Lannett (LCIN) : 0.149 - 35.22%
today: 149 - 0.285
52w: 0.149 – 3.72
mktcap: 1.6 million
https://www.findacode.com/ndc/labelers/Lannett_Company%2C_Inc.
Shares Outstanding 10.77M
Float 8.39M
Total Cash (mrq) 55.85M
Total Debt (mrq) 635.37M
Results of Insulin Study
The pivotal clinical trial of biosimilar insulin glargine demonstrated positive results, in line with prior expectations. The Company is co-developing this product with its strategic alliance partners within the HEC Group of companies (HEC). The single center, single-dose, double-blind, randomized, two-period, two-treatment, two-sequence, crossover study was designed to demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) similarity between Lannett/HECs biosimilar insulin glargine and US-Lantus® using the euglycemic clamp technique in healthy male adult volunteers. The study met all of its primary and secondary endpoints and no serious adverse events were reported. The data from the pivotal trial of the Company's biosimilar insulin glargine indicate that its insulin glargine is biosimilar to the reference product.
"We are pleased with the results of this crucial clinical trial of biosimilar insulin glargine," said Tim Crew, chief executive officer of Lannett. "We remain confident that biosimilar insulin glargine represents a significant commercial opportunity, and our team is diligently focused on advancing this product."
Lannett is moving forward expeditiously to complete the Biologics License Application, with the goal of submitting the application to the FDA within the next several months. Prior to filing, there are additional meaningful activities to complete, including a device differentiation study, which will run in April, and more comparability work showing HEC's insulin glargine is biosimilar to US sourced Lantus. Lannett also anticipates engaging with the FDA in a pre-submission meeting. There are significant steps necessary for the Company to receive FDA approval to effectively commercialize this product, and there is no guarantee that the Company will be successful in this regard.
The Company continues to assess the potential impacts of recent developments in the insulin market, including announcements by manufacturers related to lowering the price of insulin for patients, especially list prices, and enhancing market transparency. Lannett welcomes these initiatives to help drive greater access to this critical medicine and believes these changes dovetail with the Company's promising go-to-market approach.
Q2 Business and Financial Highlights:
• Net Sales were $80.9 Million
• Gross Margin was 18%, Adjusted Gross Margin was 19%
• Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters
• $19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31st
Pipeline Updates:
• Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023
• Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current Year
• Executed Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin Products Upon Approval
• Generic FLOVENT® DISKUS® ANDA Filing Anticipated by Mid Year
Apr 24, 2023 0.2300 0.2850 0.2094 0.2850 0.2850 40,646
Apr 21, 2023 0.3500 0.3500 0.2300 0.2300 0.2300 668,300
Apr 20, 2023 0.6600 0.7000 0.2500 0.3330 0.3330 1,167,800
Apr 19, 2023 0.6500 0.7196 0.6501 0.6855 0.6855 280,660
Apr 18, 2023 0.6530 0.6829 0.6530 0.6600 0.6600 30,585
Apr 17, 2023 0.7000 0.7000 0.6525 0.6525 0.6525 39,745
Apr 14, 2023 0.6400 0.7200 0.6375 0.6900 0.6900 129,657
Apr 13, 2023 0.6400 0.6960 0.6400 0.6700 0.6700 60,850
Apr 12, 2023 0.7600 0.7700 0.6600 0.6620 0.6620 126,490
Apr 11, 2023 0.9400 0.9478 0.7200 0.7221 0.7221 185,385
Apr 10, 2023 0.9750 0.9800 0.9067 0.9179 0.9179 30,979
Apr 06, 2023 0.9400 0.9500 0.9100 0.9205 0.9205 72,475
Apr 05, 2023 0.9800 0.9975 0.9300 0.9539 0.9539 312,304
Apr 04, 2023 1.8500 1.8500 0.8600 0.9700 0.9700 982,984
Apr 03, 2023 1.6800 1.8900 1.6800 1.8700 1.8700 25,574
VNET GROUP INC. (VNET) : 2.92
52w : 2.9 - 6.92
VNET Group Inc, formerly 21Vianet Group Inc, is a carrier-neutral Internet data center services provider. The Company hosts its customers' servers and networking equipment and provides interconnectivity. The Company also provides managed network services to enable customers to deliver data across the Internet through its data transmission network and smart routing technology. The Company provides value-added services, such as content delivery network services, virtual private network services and last-mile wired broadband services. It offers public cloud services, private cloud and hybrid services. The Company also offers container-based data center service. The Company's service offerings include hosting and related services, and managed network services. The Company provides hosting and related services to house servers and networking equipment in its data centers and connects them through its data transmission network, and offers other hosting related value-added services.
VNET GROUP INC. (VNET) : 2.92
52w : 2.9 - 6.92
VNET Group Inc, formerly 21Vianet Group Inc, is a carrier-neutral Internet data center services provider. The Company hosts its customers' servers and networking equipment and provides interconnectivity. The Company also provides managed network services to enable customers to deliver data across the Internet through its data transmission network and smart routing technology. The Company provides value-added services, such as content delivery network services, virtual private network services and last-mile wired broadband services. It offers public cloud services, private cloud and hybrid services. The Company also offers container-based data center service. The Company's service offerings include hosting and related services, and managed network services. The Company provides hosting and related services to house servers and networking equipment in its data centers and connects them through its data transmission network, and offers other hosting related value-added services.
U.S. ENERGY (USEG) : 1.35
52w: 1.22 - 5.28
U.S. Energy Corp. is an independent energy company. It is focused on the acquisition and development of oil and natural gas producing properties in the continental United States. Its properties and operations are in the Rockies region (Montana, Wyoming and North Dakota), the Mid-Continent (Oklahoma, Kansas and North and East Texas), West Texas, South Texas and Gulf Coast regions. It participates in oil and natural gas projects as both a non-operating working interest owner through exploration and development agreements with various oil and natural gas exploration and production companies and as an operator. It is also pursuing potential acquisitions of exploration, development and production-stage oil and natural gas properties or companies. It owns working interests in a geographically and geologically diverse portfolio of oil-weighted prospects in varying stages of exploration and development. Its oil and natural gas leases covered over 314,550 gross acres and 170,196 net acres.
Apr 01, 2023 2.1000 2.6900 1.2200 1.2700 1.2700 21,625,000
Mar 01, 2023 2.1700 2.2100 1.6600 1.7600 1.7600 1,118,000
Feb 09, 2023 0.023 Dividend
Feb 01, 2023 2.4200 2.5100 2.1600 2.1600 2.1395 708,900
Jan 01, 2023 2.3000 2.6200 2.2200 2.4300 2.4069 686,100
Dec 01, 2022 2.7300 2.7300 2.1700 2.3000 2.2781 1,400,000
Nov 07, 2022 0.023 Dividend
Nov 01, 2022 2.9500 3.0700 2.4900 2.6600 2.6140 1,529,500
Oct 01, 2022 3.0000 3.2300 2.7500 2.9800 2.9284 2,165,500
Sep 01, 2022 3.4000 3.9400 2.6700 2.9200 2.8695 3,529,400
Aug 05, 2022 0.023 Dividend
Aug 01, 2022 3.5000 4.2400 3.3000 3.4700 3.3867 4,419,700
Jul 01, 2022 3.4300 3.8400 3.2600 3.5300 3.4452 1,276,000
Jun 01, 2022 4.4100 5.2800 3.3700 3.4600 3.3769 8,493,600
May 01, 2022 3.8100 4.6500 3.6700 4.4400 4.3334 6,559,700
Apr 13, 2022 0.023 Dividend
Apr 01, 2022 4.3700 5.1900 3.7400 3.8500 3.7370 8,696,000
Mar 01, 2022 3.9800 13.9200 3.7500 4.3500 4.2223 86,797,700
U.S. ENERGY (USEG) : 1.35
52w: 1.22 - 5.28
U.S. Energy Corp. is an independent energy company. It is focused on the acquisition and development of oil and natural gas producing properties in the continental United States. Its properties and operations are in the Rockies region (Montana, Wyoming and North Dakota), the Mid-Continent (Oklahoma, Kansas and North and East Texas), West Texas, South Texas and Gulf Coast regions. It participates in oil and natural gas projects as both a non-operating working interest owner through exploration and development agreements with various oil and natural gas exploration and production companies and as an operator. It is also pursuing potential acquisitions of exploration, development and production-stage oil and natural gas properties or companies. It owns working interests in a geographically and geologically diverse portfolio of oil-weighted prospects in varying stages of exploration and development. Its oil and natural gas leases covered over 314,550 gross acres and 170,196 net acres.
Apr 01, 2023 2.1000 2.6900 1.2200 1.2700 1.2700 21,625,000
Mar 01, 2023 2.1700 2.2100 1.6600 1.7600 1.7600 1,118,000
Feb 09, 2023 0.023 Dividend
Feb 01, 2023 2.4200 2.5100 2.1600 2.1600 2.1395 708,900
Jan 01, 2023 2.3000 2.6200 2.2200 2.4300 2.4069 686,100
Dec 01, 2022 2.7300 2.7300 2.1700 2.3000 2.2781 1,400,000
Nov 07, 2022 0.023 Dividend
Nov 01, 2022 2.9500 3.0700 2.4900 2.6600 2.6140 1,529,500
Oct 01, 2022 3.0000 3.2300 2.7500 2.9800 2.9284 2,165,500
Sep 01, 2022 3.4000 3.9400 2.6700 2.9200 2.8695 3,529,400
Aug 05, 2022 0.023 Dividend
Aug 01, 2022 3.5000 4.2400 3.3000 3.4700 3.3867 4,419,700
Jul 01, 2022 3.4300 3.8400 3.2600 3.5300 3.4452 1,276,000
Jun 01, 2022 4.4100 5.2800 3.3700 3.4600 3.3769 8,493,600
May 01, 2022 3.8100 4.6500 3.6700 4.4400 4.3334 6,559,700
Apr 13, 2022 0.023 Dividend
Apr 01, 2022 4.3700 5.1900 3.7400 3.8500 3.7370 8,696,000
Mar 01, 2022 3.9800 13.9200 3.7500 4.3500 4.2223 86,797,700
TAOPING (TAOP) : 0.6503
52w: 0.55 - 1.75
Taoping Inc is a China-based company mainly providing cloud-app technologies for Smart City Internet of Things (IoT) platforms, digital advertising delivery, and other internet-based information distribution systems. The Company primarily operates through three segments. The Cloud-based Technology (CBT) segment mainly provides cloud-based products, high-end data storage servers and related services applied in private sectors including new media, healthcare, education and residential community management, and among other industries and applications. The Blockchain Technology (BT) segment is mainly engaged in cryptocurrency mining. The Traditional Information Technology (TIT) segment is mainly engaged in sales of project-based technology products and services and solutions, mainly including Geographic Information Systems (GIS), Digital Public Security Technology (DPST), and Digital Hospital Information Systems (DHIS).
TAOPING (TAOP) : 0.6503
52w: 0.55 - 1.75
Taoping Inc is a China-based company mainly providing cloud-app technologies for Smart City Internet of Things (IoT) platforms, digital advertising delivery, and other internet-based information distribution systems. The Company primarily operates through three segments. The Cloud-based Technology (CBT) segment mainly provides cloud-based products, high-end data storage servers and related services applied in private sectors including new media, healthcare, education and residential community management, and among other industries and applications. The Blockchain Technology (BT) segment is mainly engaged in cryptocurrency mining. The Traditional Information Technology (TIT) segment is mainly engaged in sales of project-based technology products and services and solutions, mainly including Geographic Information Systems (GIS), Digital Public Security Technology (DPST), and Digital Hospital Information Systems (DHIS).
RECON TECHNOLOGY (RCON) : 0.4201
52w: 0.2827 - 2.13
Shares Outstanding 40.53M
Float 27.78M
Total Cash (mrq) 269.11M
Total Cash Per Share (mrq) 7.96
Total Debt (mrq) 31.5M
Recon Technology, Ltd. provides hardware, software, and on-site services to companies in the petroleum mining and extraction industry in the People's Republic of China. The company offers equipment, tools, and other components and parts related to oilfield production and other energy industries; and develops and sells industrial automation control and information solutions. It also provides equipment for oil and gas production and transportation, including heating furnaces and burner, as well as enhancing techniques comprising packers of fracturing; production packers; sand prevention in oil and water wells; water locating and plugging techniques; fissure shaper; fracture acidizing techniques; and electronic broken-down services to resolve block-up and freezing problems. In addition, the company offers automation systems and services, including pumping unit controller that monitors the pumping units and collects data; RTU to monitor natural gas wells and collect gas well pressure data; wireless dynamometers and wireless pressure gauges; electric multi-way valves for oilfield metering station flow control; and natural gas flow computer systems. Further, it provides Recon SCADA oilfield monitor and data acquisition system for supervision and data collection; EPC service of pipeline SCADA system for pipeline monitoring and data acquisition; EPC service of oil and gas wells SCADA system for monitoring and data acquisition of oil wells and natural gas wells; EPC service of oilfield video surveillance and control system to control the oil and gas wellhead and measurement station areas; and technique service for digital oilfield transformation. Additionally, the company offers oilfield waste water treatment solutions and related chemicals; oily sludge disposal solutions; and gas station operation and management solution. Recon Technology, Ltd. was incorporated in 2007 and is headquartered in Beijing, the People's Republic of China.
On March 2, 2023, the Company announced that it has formulated preliminary plans to expand into the plastics chemical recycling business. Recon also attended the 27th China Plastics Recycling Conference and Exhibition held on February 28 at Dongguan City of Guangdong Province to explore cutting-edge technologies that work to achieve circular economy goals in eliminating waste and pollution, keeping products and materials in continuous use, and regenerating natural systems..
On February 27, 2023, the Company announced that the mainland China variable interest entity's subsidiary, Nanjing Recon Technology Co., had achieved preliminary progress on the research and development of a new energy-efficient electric pump that is being conducted at some oilfield sites in China.
RECON TECHNOLOGY (RCON) : 0.4201
52w: 0.2827 - 2.13
Shares Outstanding 40.53M
Float 27.78M
Total Cash (mrq) 269.11M
Total Cash Per Share (mrq) 7.96
Total Debt (mrq) 31.5M
Recon Technology, Ltd. provides hardware, software, and on-site services to companies in the petroleum mining and extraction industry in the People's Republic of China. The company offers equipment, tools, and other components and parts related to oilfield production and other energy industries; and develops and sells industrial automation control and information solutions. It also provides equipment for oil and gas production and transportation, including heating furnaces and burner, as well as enhancing techniques comprising packers of fracturing; production packers; sand prevention in oil and water wells; water locating and plugging techniques; fissure shaper; fracture acidizing techniques; and electronic broken-down services to resolve block-up and freezing problems. In addition, the company offers automation systems and services, including pumping unit controller that monitors the pumping units and collects data; RTU to monitor natural gas wells and collect gas well pressure data; wireless dynamometers and wireless pressure gauges; electric multi-way valves for oilfield metering station flow control; and natural gas flow computer systems. Further, it provides Recon SCADA oilfield monitor and data acquisition system for supervision and data collection; EPC service of pipeline SCADA system for pipeline monitoring and data acquisition; EPC service of oil and gas wells SCADA system for monitoring and data acquisition of oil wells and natural gas wells; EPC service of oilfield video surveillance and control system to control the oil and gas wellhead and measurement station areas; and technique service for digital oilfield transformation. Additionally, the company offers oilfield waste water treatment solutions and related chemicals; oily sludge disposal solutions; and gas station operation and management solution. Recon Technology, Ltd. was incorporated in 2007 and is headquartered in Beijing, the People's Republic of China.
On March 2, 2023, the Company announced that it has formulated preliminary plans to expand into the plastics chemical recycling business. Recon also attended the 27th China Plastics Recycling Conference and Exhibition held on February 28 at Dongguan City of Guangdong Province to explore cutting-edge technologies that work to achieve circular economy goals in eliminating waste and pollution, keeping products and materials in continuous use, and regenerating natural systems..
On February 27, 2023, the Company announced that the mainland China variable interest entity's subsidiary, Nanjing Recon Technology Co., had achieved preliminary progress on the research and development of a new energy-efficient electric pump that is being conducted at some oilfield sites in China.
ATERIAN (ATER) : 0,72095 -6,22%
52w : 0.672 - 5.78
Total Cash (mrq) 43.57M
Total Cash Per Share (mrq) 0.57
Total Debt (mrq) 22.75M
Shares Outstanding 81M
Float 60.06M
Aterian, Inc., together with its subsidiaries, operates as a technology-enabled consumer products company in North America and internationally. It provides Artificial Intelligence Marketplace e-Commerce Engine, a software technology platform, which uses machine learning, natural language processing, and data analytics to design, develop, market, and sell products. The company's platform offers home and kitchen appliances; kitchenware; heating, cooling, and air quality appliances, such as dehumidifiers, humidifiers, and air conditioners; health and beauty products; and essential oils under the hOmeLabs, Vremi, Squatty Potty, Xtava, RIF6, Aussie Health, Holonix, Truweo, Mueller, Pursteam, Pohl and Schmitt, Healing Solutions, Photo Paper Direct, Step and Go, and Spiralizer brands. It primarily serves individual online consumers through Amazon and other e-commerce platforms, as well as through its owned and operated websites and other marketplaces. The company was formerly known as Mohawk Group Holdings, Inc. and changed its name to Aterian, Inc. in April 2021. Aterian, Inc. was founded in 2014 and is headquartered in New York, New York.
Apr 01, 2023 0.9000 0.9500 0.7630 0.7690 0.7690 9,214,600
Mar 01, 2023 1.1700 1.2100 0.7620 0.8600 0.8600 17,820,700
Feb 01, 2023 1.5000 1.6830 1.1300 1.2000 1.2000 30,650,600
Jan 01, 2023 0.7900 1.6500 0.7100 1.5300 1.5300 80,268,800
Dec 01, 2022 1.0600 1.2000 0.6720 0.7700 0.7700 21,328,400
Nov 01, 2022 1.1100 1.2800 0.9900 1.0800 1.0800 26,208,700
Oct 01, 2022 1.2800 1.3300 0.9650 1.1000 1.1000 52,227,400
Sep 01, 2022 2.2800 2.7700 1.1910 1.2400 1.2400 46,771,500
Aug 01, 2022 2.2500 3.5800 2.2000 2.2800 2.2800 51,640,500
Jul 01, 2022 2.1300 2.7200 2.1300 2.2800 2.2800 35,127,600
Jun 01, 2022 3.2300 3.4600 2.1000 2.1600 2.1600 74,636,800
May 01, 2022 5.1700 5.7100 2.5200 3.2300 3.2300 186,045,100
Apr 01, 2022 2.4700 7.2600 2.3000 5.1300 5.1300 1,086,055,400
Mar 01, 2022 3.0000 3.0550 2.1000 2.4300 2.4300 76,630,400
Feb 01, 2022 3.2400 3.9100 2.6100 2.9900 2.9900 35,313,100
Jan 01, 2022 4.1700 4.3100 2.4500 3.2400 3.2400 68,789,700
Dec 01, 2021 4.9700 5.8000 3.7200 4.1100 4.1100 80,529,400
Nov 01, 2021 6.4000 8.3100 4.6500 4.8800 4.8800 129,029,900
Oct 01, 2021 11.2020 11.5300 6.2900 6.3900 6.3900 233,582,400
Sep 01, 2021 5.8320 19.1000 5.6400 10.8300 10.8300 1,263,945,800
Aug 01, 2021 9.2700 9.6100 3.0400 5.9600 5.9600 167,666,900
Jul 01, 2021 14.6300 15.3800 8.7800 9.0300 9.0300 14,157,200
Jun 01, 2021 18.0000 21.0700 14.3700 14.6300 14.6300 18,025,800
May 01, 2021 22.1100 22.1900 11.8100 17.9500 17.9500 24,448,700
Apr 01, 2021 31.0200 33.9700 19.6400 21.7000 21.7000 18,351,900
Mar 01, 2021 41.0100 47.8000 26.2500 29.5000 29.5000 28,614,700
Feb 01, 2021 24.0000 48.9900 22.3000 39.8800 39.8800 19,112,400
ATERIAN (ATER) : 0,72095 -6,22%
52w : 0.672 - 5.78
Total Cash (mrq) 43.57M
Total Cash Per Share (mrq) 0.57
Total Debt (mrq) 22.75M
Shares Outstanding 81M
Float 60.06M
Aterian, Inc., together with its subsidiaries, operates as a technology-enabled consumer products company in North America and internationally. It provides Artificial Intelligence Marketplace e-Commerce Engine, a software technology platform, which uses machine learning, natural language processing, and data analytics to design, develop, market, and sell products. The company's platform offers home and kitchen appliances; kitchenware; heating, cooling, and air quality appliances, such as dehumidifiers, humidifiers, and air conditioners; health and beauty products; and essential oils under the hOmeLabs, Vremi, Squatty Potty, Xtava, RIF6, Aussie Health, Holonix, Truweo, Mueller, Pursteam, Pohl and Schmitt, Healing Solutions, Photo Paper Direct, Step and Go, and Spiralizer brands. It primarily serves individual online consumers through Amazon and other e-commerce platforms, as well as through its owned and operated websites and other marketplaces. The company was formerly known as Mohawk Group Holdings, Inc. and changed its name to Aterian, Inc. in April 2021. Aterian, Inc. was founded in 2014 and is headquartered in New York, New York.
Apr 01, 2023 0.9000 0.9500 0.7630 0.7690 0.7690 9,214,600
Mar 01, 2023 1.1700 1.2100 0.7620 0.8600 0.8600 17,820,700
Feb 01, 2023 1.5000 1.6830 1.1300 1.2000 1.2000 30,650,600
Jan 01, 2023 0.7900 1.6500 0.7100 1.5300 1.5300 80,268,800
Dec 01, 2022 1.0600 1.2000 0.6720 0.7700 0.7700 21,328,400
Nov 01, 2022 1.1100 1.2800 0.9900 1.0800 1.0800 26,208,700
Oct 01, 2022 1.2800 1.3300 0.9650 1.1000 1.1000 52,227,400
Sep 01, 2022 2.2800 2.7700 1.1910 1.2400 1.2400 46,771,500
Aug 01, 2022 2.2500 3.5800 2.2000 2.2800 2.2800 51,640,500
Jul 01, 2022 2.1300 2.7200 2.1300 2.2800 2.2800 35,127,600
Jun 01, 2022 3.2300 3.4600 2.1000 2.1600 2.1600 74,636,800
May 01, 2022 5.1700 5.7100 2.5200 3.2300 3.2300 186,045,100
Apr 01, 2022 2.4700 7.2600 2.3000 5.1300 5.1300 1,086,055,400
Mar 01, 2022 3.0000 3.0550 2.1000 2.4300 2.4300 76,630,400
Feb 01, 2022 3.2400 3.9100 2.6100 2.9900 2.9900 35,313,100
Jan 01, 2022 4.1700 4.3100 2.4500 3.2400 3.2400 68,789,700
Dec 01, 2021 4.9700 5.8000 3.7200 4.1100 4.1100 80,529,400
Nov 01, 2021 6.4000 8.3100 4.6500 4.8800 4.8800 129,029,900
Oct 01, 2021 11.2020 11.5300 6.2900 6.3900 6.3900 233,582,400
Sep 01, 2021 5.8320 19.1000 5.6400 10.8300 10.8300 1,263,945,800
Aug 01, 2021 9.2700 9.6100 3.0400 5.9600 5.9600 167,666,900
Jul 01, 2021 14.6300 15.3800 8.7800 9.0300 9.0300 14,157,200
Jun 01, 2021 18.0000 21.0700 14.3700 14.6300 14.6300 18,025,800
May 01, 2021 22.1100 22.1900 11.8100 17.9500 17.9500 24,448,700
Apr 01, 2021 31.0200 33.9700 19.6400 21.7000 21.7000 18,351,900
Mar 01, 2021 41.0100 47.8000 26.2500 29.5000 29.5000 28,614,700
Feb 01, 2021 24.0000 48.9900 22.3000 39.8800 39.8800 19,112,400
CONTEXTLOGIC (WISH) : 8.015
52w: 6.86 - 63.6
Shares Outstanding 23.29M
Float 20.56M
Total Cash (mrq) 719M
Total Cash Per Share (mrq) 31.04
Total Debt (mrq) 20M
They can reduce the number of outstanding shares to 17M
SAN FRANCISCO, April 20, 2023 (GLOBE NEWSWIRE) -- ContextLogic Inc. (d/b/a Wish or the “Company”) (NASDAQ: WISH), one of the world’s largest mobile ecommerce platforms, announced today that its Board of Directors has approved a share repurchase program with authorization to repurchase up to $50 million in shares of its Class A common stock.
"We believe that the current macroeconomic environment and the strength of our balance sheet presents an attractive buying opportunity for our stock. This share repurchase program demonstrates the Board’s and management’s confidence in the future of our business and our commitment to creating long-term, sustainable value for our shareholders," said Vivian Liu, Chief Financial Officer and Chief Operating Officer of Wish. “We believe the current market does not reflect the long-term value of our shares of common stock and we believe this share repurchase program will support our efforts to unlock the long-term value and opportunity we see ahead.”
The manner, timing, and amount of any purchase will be based on an assessment of business, economic and market conditions, corporate and regulatory requirements, prevailing stock prices, and other considerations. Wish may repurchase shares of Class A common stock from time to time through open market purchases, in privately negotiated transactions, or by other means, including through the use of trading plans, each in accordance with applicable securities laws and other restrictions. The repurchase program will be effective through December 31, 2023, and may be suspended, terminated, or modified at any time for any reason, and it does not obligate the Company to purchase any particular number of shares.
About Wish
Wish brings an affordable and entertaining shopping experience to millions of consumers around the world. Since our founding in San Francisco in 2010, we have become one of the largest global ecommerce platforms, connecting millions of value-conscious consumers to merchants all over the world. Wish combines technology and data science capabilities and an innovative discovery-based mobile shopping experience to create a highly-visual, entertaining, and personalized shopping experience for its users. For more information about the company or to download the Wish mobile app, visit www.wish.com or follow @Wish on Facebook, Instagram and TikTok or @WishShopping on Twitter and YouTube.
CONTEXTLOGIC (WISH) : 8.015
52w: 6.86 - 63.6
Shares Outstanding 23.29M
Float 20.56M
Total Cash (mrq) 719M
Total Cash Per Share (mrq) 31.04
Total Debt (mrq) 20M
They can reduce the number of outstanding shares to 17M
SAN FRANCISCO, April 20, 2023 (GLOBE NEWSWIRE) -- ContextLogic Inc. (d/b/a Wish or the “Company”) (NASDAQ: WISH), one of the world’s largest mobile ecommerce platforms, announced today that its Board of Directors has approved a share repurchase program with authorization to repurchase up to $50 million in shares of its Class A common stock.
"We believe that the current macroeconomic environment and the strength of our balance sheet presents an attractive buying opportunity for our stock. This share repurchase program demonstrates the Board’s and management’s confidence in the future of our business and our commitment to creating long-term, sustainable value for our shareholders," said Vivian Liu, Chief Financial Officer and Chief Operating Officer of Wish. “We believe the current market does not reflect the long-term value of our shares of common stock and we believe this share repurchase program will support our efforts to unlock the long-term value and opportunity we see ahead.”
The manner, timing, and amount of any purchase will be based on an assessment of business, economic and market conditions, corporate and regulatory requirements, prevailing stock prices, and other considerations. Wish may repurchase shares of Class A common stock from time to time through open market purchases, in privately negotiated transactions, or by other means, including through the use of trading plans, each in accordance with applicable securities laws and other restrictions. The repurchase program will be effective through December 31, 2023, and may be suspended, terminated, or modified at any time for any reason, and it does not obligate the Company to purchase any particular number of shares.
About Wish
Wish brings an affordable and entertaining shopping experience to millions of consumers around the world. Since our founding in San Francisco in 2010, we have become one of the largest global ecommerce platforms, connecting millions of value-conscious consumers to merchants all over the world. Wish combines technology and data science capabilities and an innovative discovery-based mobile shopping experience to create a highly-visual, entertaining, and personalized shopping experience for its users. For more information about the company or to download the Wish mobile app, visit www.wish.com or follow @Wish on Facebook, Instagram and TikTok or @WishShopping on Twitter and YouTube.
CRSM : 0.0024
CarSmartt, Inc.
https://smarttholdings.com/
https://www.otcmarkets.com/stock/CRSM/disclosure
Our share structure has remained the same since 2 years.
As of 08/30/2021, the number of shares outstanding of our Common Stock was:
595,304,566
04/18/2023
Outstanding Shares
595,304,566
175,117,101
11/02/2022
= less than 350.000 in the free float.
CURRENT ASSETS:
Total Current Assets 4,324
Investments 74,005
Deposit - Acquistion 1,765,707
Computer software 72,000
Loan receivable 184,453
Total Assets $ 2,100,489
no dilution so room for a big rebound
Jul 26, 2021 0.0550
https://blackbrickconstruction.com/
In June, we acquired Black Brick Construction, which specializes in ground up construction. The company has over $100K in positive cash flow and three new projects with potential for more growth.
https://smarttholdings.com/#
https://smarttholdings.com/real-estate/
https://smarttholdings.com/projects/
Smartt Inc. has purchased shares of Coinbase, netflix, fubotv, palantir and tqqq
CarSmartt entered in to an agreement with Archer Robotics, LLC., to establish a project and implementation plan to provide an autonomous vehicle platform for CarSmartt, focused on Parcels delivery with driverless cars.
Exciting things to look forward to:
– News on New Strategic Acquisitions
– News on NFTs and Cryptocurrency.
"We are excited to reveal with our Shareholders the new direction of the company, and we are ready to bring exponential shareholder value. Our commitment is to our shareholders, and we are confident that we won't let you down as we embark on this new exciting chapter."
CRSM : 0.0024
CarSmartt, Inc.
https://smarttholdings.com/
https://www.otcmarkets.com/stock/CRSM/disclosure
Our share structure has remained the same since 2 years.
As of 08/30/2021, the number of shares outstanding of our Common Stock was:
595,304,566
04/18/2023
Outstanding Shares
595,304,566
175,117,101
11/02/2022
= less than 350.000 in the free float.
CURRENT ASSETS:
Total Current Assets 4,324
Investments 74,005
Deposit - Acquistion 1,765,707
Computer software 72,000
Loan receivable 184,453
Total Assets $ 2,100,489
no dilution so room for a big rebound
Jul 26, 2021 0.0550
https://blackbrickconstruction.com/
In June, we acquired Black Brick Construction, which specializes in ground up construction. The company has over $100K in positive cash flow and three new projects with potential for more growth.
https://smarttholdings.com/#
https://smarttholdings.com/real-estate/
https://smarttholdings.com/projects/
Smartt Inc. has purchased shares of Coinbase, netflix, fubotv, palantir and tqqq
CarSmartt entered in to an agreement with Archer Robotics, LLC., to establish a project and implementation plan to provide an autonomous vehicle platform for CarSmartt, focused on Parcels delivery with driverless cars.
Exciting things to look forward to:
– News on New Strategic Acquisitions
– News on NFTs and Cryptocurrency.
"We are excited to reveal with our Shareholders the new direction of the company, and we are ready to bring exponential shareholder value. Our commitment is to our shareholders, and we are confident that we won't let you down as we embark on this new exciting chapter."
CRSM : 0.0024
52w: 0.0016 - 0.0064
https://twitter.com/matty_trader/status/1649074521364676608/photo/1
CarSmartt, Inc.
https://smarttholdings.com/
https://www.otcmarkets.com/stock/CRSM/disclosure
Our share structure has remained the same since 2 years.
As of 08/30/2021, the number of shares outstanding of our Common Stock was:
595,304,566
04/18/2023
Outstanding Shares
595,304,566
175,117,101
11/02/2022
= less than 350.000 in the free float.
CURRENT ASSETS:
Total Current Assets 4,324
Investments 74,005
Deposit - Acquistion 1,765,707
Computer software 72,000
Loan receivable 184,453
Total Assets $ 2,100,489
no dilution so room for a big rebound
Jul 26, 2021 0.0550
https://blackbrickconstruction.com/
In June, we acquired Black Brick Construction, which specializes in ground up construction. The company has over $100K in positive cash flow and three new projects with potential for more growth.
Smartt Inc. has purchased shares of Coinbase, netflix, fubotv, palantir and tqqq
CarSmartt entered in to an agreement with Archer Robotics, LLC., to establish a project and implementation plan to provide an autonomous vehicle platform for CarSmartt, focused on Parcels delivery with driverless cars.
Exciting things to look forward to:
– News on New Strategic Acquisitions
– News on NFTs and Cryptocurrency.
"We are excited to reveal with our Shareholders the new direction of the company, and we are ready to bring exponential shareholder value. Our commitment is to our shareholders, and we are confident that we won't let you down as we embark on this new exciting chapter."
CRSM : 0.0024
52w: 0.0016 - 0.0064
https://twitter.com/matty_trader/status/1649074521364676608/photo/1
CarSmartt, Inc.
https://smarttholdings.com/
https://www.otcmarkets.com/stock/CRSM/disclosure
Our share structure has remained the same since 2 years.
As of 08/30/2021, the number of shares outstanding of our Common Stock was:
595,304,566
04/18/2023
Outstanding Shares
595,304,566
175,117,101
11/02/2022
= less than 350.000 in the free float.
CURRENT ASSETS:
Total Current Assets 4,324
Investments 74,005
Deposit - Acquistion 1,765,707
Computer software 72,000
Loan receivable 184,453
Total Assets $ 2,100,489
no dilution so room for a big rebound
Jul 26, 2021 0.0550
https://blackbrickconstruction.com/
In June, we acquired Black Brick Construction, which specializes in ground up construction. The company has over $100K in positive cash flow and three new projects with potential for more growth.
Smartt Inc. has purchased shares of Coinbase, netflix, fubotv, palantir and tqqq
CarSmartt entered in to an agreement with Archer Robotics, LLC., to establish a project and implementation plan to provide an autonomous vehicle platform for CarSmartt, focused on Parcels delivery with driverless cars.
Exciting things to look forward to:
– News on New Strategic Acquisitions
– News on NFTs and Cryptocurrency.
"We are excited to reveal with our Shareholders the new direction of the company, and we are ready to bring exponential shareholder value. Our commitment is to our shareholders, and we are confident that we won't let you down as we embark on this new exciting chapter."
Lannett (LCIN) : 0.32
52w: 0.32 – 3.72
Shares Outstanding 10.77M
Float 8.39M
Q2 Business and Financial Highlights:
• Net Sales were $80.9 Million
• Gross Margin was 18%, Adjusted Gross Margin was 19%
• Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters
• $19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31st
Pipeline Updates:
• Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023
• Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current Year
• Executed Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin Products Upon Approval
• Generic FLOVENT® DISKUS® ANDA Filing Anticipated by Mid Year
Apr 19, 2023 0.6500 0.7196 0.6501 0.6855 0.6855 280,660
Apr 18, 2023 0.6530 0.6829 0.6530 0.6600 0.6600 30,585
Apr 17, 2023 0.7000 0.7000 0.6525 0.6525 0.6525 39,745
Apr 14, 2023 0.6400 0.7200 0.6375 0.6900 0.6900 129,657
Apr 13, 2023 0.6400 0.6960 0.6400 0.6700 0.6700 60,850
Apr 12, 2023 0.7600 0.7700 0.6600 0.6620 0.6620 126,490
Apr 11, 2023 0.9400 0.9478 0.7200 0.7221 0.7221 185,385
Apr 10, 2023 0.9750 0.9800 0.9067 0.9179 0.9179 30,979
Apr 06, 2023 0.9400 0.9500 0.9100 0.9205 0.9205 72,475
Apr 05, 2023 0.9800 0.9975 0.9300 0.9539 0.9539 312,304
Apr 04, 2023 1.8500 1.8500 0.8600 0.9700 0.9700 982,984
Apr 03, 2023 1.6800 1.8900 1.6800 1.8700 1.8700 25,574
Lannett (LCIN) : 0.32
52w: 0.32 – 3.72
Shares Outstanding 10.77M
Float 8.39M
Q2 Business and Financial Highlights:
• Net Sales were $80.9 Million
• Gross Margin was 18%, Adjusted Gross Margin was 19%
• Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters
• $19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31st
Pipeline Updates:
• Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023
• Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current Year
• Executed Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin Products Upon Approval
• Generic FLOVENT® DISKUS® ANDA Filing Anticipated by Mid Year
Apr 19, 2023 0.6500 0.7196 0.6501 0.6855 0.6855 280,660
Apr 18, 2023 0.6530 0.6829 0.6530 0.6600 0.6600 30,585
Apr 17, 2023 0.7000 0.7000 0.6525 0.6525 0.6525 39,745
Apr 14, 2023 0.6400 0.7200 0.6375 0.6900 0.6900 129,657
Apr 13, 2023 0.6400 0.6960 0.6400 0.6700 0.6700 60,850
Apr 12, 2023 0.7600 0.7700 0.6600 0.6620 0.6620 126,490
Apr 11, 2023 0.9400 0.9478 0.7200 0.7221 0.7221 185,385
Apr 10, 2023 0.9750 0.9800 0.9067 0.9179 0.9179 30,979
Apr 06, 2023 0.9400 0.9500 0.9100 0.9205 0.9205 72,475
Apr 05, 2023 0.9800 0.9975 0.9300 0.9539 0.9539 312,304
Apr 04, 2023 1.8500 1.8500 0.8600 0.9700 0.9700 982,984
Apr 03, 2023 1.6800 1.8900 1.6800 1.8700 1.8700 25,574
Recon (RCON): pre market: 0.615 + 0.1668 (+37.22%)
Pre market volume: 485.784
Shares Outstanding 40.53M
Float 27.78M
Total Cash (mrq) 269.11M
Total Cash Per Share (mrq) 7.96
Total Debt (mrq) 31.5M
Recon Technology, Ltd. provides hardware, software, and on-site services to companies in the petroleum mining and extraction industry in the People's Republic of China. The company offers equipment, tools, and other components and parts related to oilfield production and other energy industries; and develops and sells industrial automation control and information solutions. It also provides equipment for oil and gas production and transportation, including heating furnaces and burner, as well as enhancing techniques comprising packers of fracturing; production packers; sand prevention in oil and water wells; water locating and plugging techniques; fissure shaper; fracture acidizing techniques; and electronic broken-down services to resolve block-up and freezing problems. In addition, the company offers automation systems and services, including pumping unit controller that monitors the pumping units and collects data; RTU to monitor natural gas wells and collect gas well pressure data; wireless dynamometers and wireless pressure gauges; electric multi-way valves for oilfield metering station flow control; and natural gas flow computer systems. Further, it provides Recon SCADA oilfield monitor and data acquisition system for supervision and data collection; EPC service of pipeline SCADA system for pipeline monitoring and data acquisition; EPC service of oil and gas wells SCADA system for monitoring and data acquisition of oil wells and natural gas wells; EPC service of oilfield video surveillance and control system to control the oil and gas wellhead and measurement station areas; and technique service for digital oilfield transformation. Additionally, the company offers oilfield waste water treatment solutions and related chemicals; oily sludge disposal solutions; and gas station operation and management solution. Recon Technology, Ltd. was incorporated in 2007 and is headquartered in Beijing, the People's Republic of China.
On March 2, 2023, the Company announced that it has formulated preliminary plans to expand into the plastics chemical recycling business. Recon also attended the 27th China Plastics Recycling Conference and Exhibition held on February 28 at Dongguan City of Guangdong Province to explore cutting-edge technologies that work to achieve circular economy goals in eliminating waste and pollution, keeping products and materials in continuous use, and regenerating natural systems..
On February 27, 2023, the Company announced that the mainland China variable interest entity's subsidiary, Nanjing Recon Technology Co., had achieved preliminary progress on the research and development of a new energy-efficient electric pump that is being conducted at some oilfield sites in China.
Recon (RCON): pre market: 0.615 + 0.1668 (+37.22%)
Pre market volume: 485.784
Shares Outstanding 40.53M
Float 27.78M
Total Cash (mrq) 269.11M
Total Cash Per Share (mrq) 7.96
Total Debt (mrq) 31.5M
Recon Technology, Ltd. provides hardware, software, and on-site services to companies in the petroleum mining and extraction industry in the People's Republic of China. The company offers equipment, tools, and other components and parts related to oilfield production and other energy industries; and develops and sells industrial automation control and information solutions. It also provides equipment for oil and gas production and transportation, including heating furnaces and burner, as well as enhancing techniques comprising packers of fracturing; production packers; sand prevention in oil and water wells; water locating and plugging techniques; fissure shaper; fracture acidizing techniques; and electronic broken-down services to resolve block-up and freezing problems. In addition, the company offers automation systems and services, including pumping unit controller that monitors the pumping units and collects data; RTU to monitor natural gas wells and collect gas well pressure data; wireless dynamometers and wireless pressure gauges; electric multi-way valves for oilfield metering station flow control; and natural gas flow computer systems. Further, it provides Recon SCADA oilfield monitor and data acquisition system for supervision and data collection; EPC service of pipeline SCADA system for pipeline monitoring and data acquisition; EPC service of oil and gas wells SCADA system for monitoring and data acquisition of oil wells and natural gas wells; EPC service of oilfield video surveillance and control system to control the oil and gas wellhead and measurement station areas; and technique service for digital oilfield transformation. Additionally, the company offers oilfield waste water treatment solutions and related chemicals; oily sludge disposal solutions; and gas station operation and management solution. Recon Technology, Ltd. was incorporated in 2007 and is headquartered in Beijing, the People's Republic of China.
On March 2, 2023, the Company announced that it has formulated preliminary plans to expand into the plastics chemical recycling business. Recon also attended the 27th China Plastics Recycling Conference and Exhibition held on February 28 at Dongguan City of Guangdong Province to explore cutting-edge technologies that work to achieve circular economy goals in eliminating waste and pollution, keeping products and materials in continuous use, and regenerating natural systems..
On February 27, 2023, the Company announced that the mainland China variable interest entity's subsidiary, Nanjing Recon Technology Co., had achieved preliminary progress on the research and development of a new energy-efficient electric pump that is being conducted at some oilfield sites in China.
Time to go up back again
ReShape Lifesciences Inc. (RSLS) : 3.1000+0.4500 (+16.98%)
Apr 11, 2023 2.6500 3.8900 2.6500 3.1000 3.1000 4,178,700
Apr 10, 2023 2.6800 2.7190 2.6300 2.6500 2.6500 44,700
Apr 06, 2023 2.7400 2.8700 2.6300 2.7500 2.7500 86,600
Apr 05, 2023 2.7500 2.7500 2.6200 2.6900 2.6900 39,000
Apr 04, 2023 2.7000 2.7900 2.6000 2.6800 2.6800 37,700
Apr 03, 2023 2.6000 2.9800 2.5200 2.6100 2.6100 302,100
Mar 31, 2023 2.7100 2.8600 2.5000 2.5700 2.5700 120,900
Mar 30, 2023 2.9100 3.0650 2.7700 2.8000 2.8000 40,700
Mar 29, 2023 2.8700 2.9500 2.8000 2.9300 2.9300 98,000
Mar 28, 2023 2.9800 3.1500 2.8000 3.1200 3.1200 164,100
Mar 27, 2023 3.0400 3.1700 2.7530 2.7850 2.7850 126,000
Mar 24, 2023 3.1100 3.2900 3.0000 3.0800 3.0800 51,000
Mar 23, 2023 3.0200 3.2400 2.9800 3.1400 3.1400 82,300
Mar 22, 2023 3.0000 3.3400 2.9340 3.0200 3.0200 107,000
Mar 21, 2023 2.9500 3.0400 2.6700 3.0000 3.0000 235,500
Mar 20, 2023 3.1600 3.5600 3.0000 3.0400 3.0400 1,841,200
Mar 17, 2023 2.7700 2.8100 2.4900 2.6600 2.6600 143,900
Mar 16, 2023 2.9500 2.9500 2.6900 2.7700 2.7700 139,400
Mar 15, 2023 3.0900 3.0900 2.9000 2.9800 2.9800 93,300
Mar 14, 2023 3.1300 3.2000 3.1000 3.1000 3.1000 79,700
Mar 13, 2023 3.3200 3.3290 3.0700 3.1300 3.1300 87,500
Mar 10, 2023 3.3800 3.9100 3.2000 3.3500 3.3500 275,700
Mar 09, 2023 3.7800 3.7800 3.3500 3.3500 3.3500 107,300
Mar 08, 2023 3.8200 3.8850 3.6300 3.7000 3.7000 88,200
Mar 07, 2023 4.1000 4.1000 3.7700 3.8200 3.8200 144,900
Mar 06, 2023 4.4700 4.4700 3.9800 4.0100 4.0100 114,800
Mar 03, 2023 4.3200 4.5300 4.2900 4.4700 4.4700 96,700
Mar 02, 2023 4.2400 4.4800 4.1000 4.4200 4.4200 112,100
Mar 01, 2023 4.2500 4.2500 4.0500 4.1900 4.1900 61,800
Feb 28, 2023 4.5000 4.5100 4.1100 4.1900 4.1900 122,400
Feb 27, 2023 4.0000 4.5800 4.0000 4.5600 4.5600 276,800
Feb 24, 2023 4.1500 4.2300 3.9400 4.0300 4.0300 138,100
Feb 23, 2023 4.5700 4.6780 4.1200 4.1300 4.1300 270,500
Feb 22, 2023 4.5500 4.8000 4.3200 4.7000 4.7000 310,500
Feb 21, 2023 4.9000 5.3900 4.5200 4.5600 4.5600 610,200
Feb 17, 2023 4.3300 5.5000 4.1000 5.0000 5.0000 3,712,500
Feb 16, 2023 4.3370 4.9800 4.1900 4.3400 4.3400 609,000
Feb 15, 2023 4.0500 4.5000 3.8300 4.3700 4.3700 897,500
Feb 14, 2023 4.4400 4.4400 3.9100 4.0700 4.0700 379,100
Feb 13, 2023 4.9000 4.9000 4.2500 4.3300 4.3300 568,800
Feb 10, 2023 5.3300 5.4500 5.0000 5.0200 5.0200 525,700
Feb 09, 2023 5.8700 5.9200 5.3800 5.5300 5.5300 715,000
Feb 08, 2023 6.2000 8.2000 5.5700 5.9050 5.9050 5,910,000
Feb 07, 2023 6.6500 6.7280 6.0600 6.1600 6.1600 931,200
Feb 06, 2023 6.5000 7.4500 6.3500 6.9500 6.9500 5,427,300
Feb 03, 2023 13.1400 22.4000 11.5600 17.0400 17.0400 11,669,700
Feb 02, 2023 6.6300 6.7000 6.0600 6.3000 6.3000 708,000
Feb 01, 2023 7.1100 7.3300 6.5500 6.5600 6.5600 54,000
Jan 31, 2023 7.4100 7.5800 6.8600 7.2400 7.2400 176,500
Jan 30, 2023 8.1400 8.1400 7.5200 7.8000 7.8000 16,400
Jan 27, 2023 8.4100 8.4100 7.6500 7.8700 7.8700 32,400
Jan 26, 2023 7.6400 8.4060 7.6000 8.1700 8.1700 44,600
Jan 25, 2023 7.4100 7.7500 7.3700 7.5600 7.5600 31,400
Jan 24, 2023 7.4900 7.7500 7.4000 7.5700 7.5700 29,500
Jan 23, 2023 7.5400 7.7500 7.3900 7.6700 7.6700 27,600
Jan 20, 2023 7.1800 7.7500 7.1100 7.6800 7.6800 14,900
Jan 19, 2023 7.2200 7.4800 7.2000 7.2000 7.2000 8,900
Jan 18, 2023 8.1700 8.3200 7.2900 7.3000 7.3000 29,300
Jan 17, 2023 8.3800 8.5400 7.8200 8.0500 8.0500 40,000
Jan 13, 2023 7.8100 9.1100 7.8100 8.7200 8.7200 105,300
Jan 12, 2023 7.6100 8.2000 7.6100 7.9500 7.9500 23,300
Jan 11, 2023 7.5800 8.1800 7.5800 8.0100 8.0100 38,900
Jan 10, 2023 7.4200 8.2760 7.1800 7.8100 7.8100 115,600
Jan 09, 2023 7.5100 7.6700 7.2700 7.5600 7.5600 75,100
Jan 06, 2023 7.1500 8.1700 7.0800 7.2600 7.2600 152,000
Jan 05, 2023 9.0600 9.0600 7.2600 7.5300 7.5300 211,900
Jan 04, 2023 12.3300 13.4500 8.9000 8.9000 8.9000 886,800
Jan 03, 2023 9.6600 20.6300 9.4500 15.6600 15.6600 12,363,90
MATTHEW NACHTRAB REPORTS 27.7% STAKE IN RESHAPE LIFESCIENCES AS
NACHTRAB-PURCHASED CO'S COMMON STOCK BASED ON BELIEF THAT SUCH SECURITIES, AT CURRENT MARKET PRICES, REPRESENTED AN ATTRACTIVE INVESTMENT OPPORTUNITY
NACHTRAB - WROTE A LETTER TO THE CEO OF CO WITH RECOMMENDATIONS FOR THE MANAGEMENT TEAM’S STRATEGY GOING FORWARD
https://ir.reshapelifesciences.com/static-files/aa8a67f3-70fe-4b27-aa86-95ba8c3ce91a
I am excited for your new tenure as CEO of ReShape Lifesciences and I believe your team can rebuild and create a $100m plus market cap company with some austerity measures, leveraging assets currently owned, and capitalizing on the medicated weight loss secular trend to generate lead flow and massive revenue growth. I am willing to discuss this and advise in any way I can help.
very low free float: 442.49k
Estimated share price by March 20, 2024.
2023-03-20 2024-03-20 High 52.50 Average 39.52 Low 27.78
Time to go up back again
ReShape Lifesciences Inc. (RSLS) : 3.1000+0.4500 (+16.98%)
Apr 11, 2023 2.6500 3.8900 2.6500 3.1000 3.1000 4,178,700
Apr 10, 2023 2.6800 2.7190 2.6300 2.6500 2.6500 44,700
Apr 06, 2023 2.7400 2.8700 2.6300 2.7500 2.7500 86,600
Apr 05, 2023 2.7500 2.7500 2.6200 2.6900 2.6900 39,000
Apr 04, 2023 2.7000 2.7900 2.6000 2.6800 2.6800 37,700
Apr 03, 2023 2.6000 2.9800 2.5200 2.6100 2.6100 302,100
Mar 31, 2023 2.7100 2.8600 2.5000 2.5700 2.5700 120,900
Mar 30, 2023 2.9100 3.0650 2.7700 2.8000 2.8000 40,700
Mar 29, 2023 2.8700 2.9500 2.8000 2.9300 2.9300 98,000
Mar 28, 2023 2.9800 3.1500 2.8000 3.1200 3.1200 164,100
Mar 27, 2023 3.0400 3.1700 2.7530 2.7850 2.7850 126,000
Mar 24, 2023 3.1100 3.2900 3.0000 3.0800 3.0800 51,000
Mar 23, 2023 3.0200 3.2400 2.9800 3.1400 3.1400 82,300
Mar 22, 2023 3.0000 3.3400 2.9340 3.0200 3.0200 107,000
Mar 21, 2023 2.9500 3.0400 2.6700 3.0000 3.0000 235,500
Mar 20, 2023 3.1600 3.5600 3.0000 3.0400 3.0400 1,841,200
Mar 17, 2023 2.7700 2.8100 2.4900 2.6600 2.6600 143,900
Mar 16, 2023 2.9500 2.9500 2.6900 2.7700 2.7700 139,400
Mar 15, 2023 3.0900 3.0900 2.9000 2.9800 2.9800 93,300
Mar 14, 2023 3.1300 3.2000 3.1000 3.1000 3.1000 79,700
Mar 13, 2023 3.3200 3.3290 3.0700 3.1300 3.1300 87,500
Mar 10, 2023 3.3800 3.9100 3.2000 3.3500 3.3500 275,700
Mar 09, 2023 3.7800 3.7800 3.3500 3.3500 3.3500 107,300
Mar 08, 2023 3.8200 3.8850 3.6300 3.7000 3.7000 88,200
Mar 07, 2023 4.1000 4.1000 3.7700 3.8200 3.8200 144,900
Mar 06, 2023 4.4700 4.4700 3.9800 4.0100 4.0100 114,800
Mar 03, 2023 4.3200 4.5300 4.2900 4.4700 4.4700 96,700
Mar 02, 2023 4.2400 4.4800 4.1000 4.4200 4.4200 112,100
Mar 01, 2023 4.2500 4.2500 4.0500 4.1900 4.1900 61,800
Feb 28, 2023 4.5000 4.5100 4.1100 4.1900 4.1900 122,400
Feb 27, 2023 4.0000 4.5800 4.0000 4.5600 4.5600 276,800
Feb 24, 2023 4.1500 4.2300 3.9400 4.0300 4.0300 138,100
Feb 23, 2023 4.5700 4.6780 4.1200 4.1300 4.1300 270,500
Feb 22, 2023 4.5500 4.8000 4.3200 4.7000 4.7000 310,500
Feb 21, 2023 4.9000 5.3900 4.5200 4.5600 4.5600 610,200
Feb 17, 2023 4.3300 5.5000 4.1000 5.0000 5.0000 3,712,500
Feb 16, 2023 4.3370 4.9800 4.1900 4.3400 4.3400 609,000
Feb 15, 2023 4.0500 4.5000 3.8300 4.3700 4.3700 897,500
Feb 14, 2023 4.4400 4.4400 3.9100 4.0700 4.0700 379,100
Feb 13, 2023 4.9000 4.9000 4.2500 4.3300 4.3300 568,800
Feb 10, 2023 5.3300 5.4500 5.0000 5.0200 5.0200 525,700
Feb 09, 2023 5.8700 5.9200 5.3800 5.5300 5.5300 715,000
Feb 08, 2023 6.2000 8.2000 5.5700 5.9050 5.9050 5,910,000
Feb 07, 2023 6.6500 6.7280 6.0600 6.1600 6.1600 931,200
Feb 06, 2023 6.5000 7.4500 6.3500 6.9500 6.9500 5,427,300
Feb 03, 2023 13.1400 22.4000 11.5600 17.0400 17.0400 11,669,700
Feb 02, 2023 6.6300 6.7000 6.0600 6.3000 6.3000 708,000
Feb 01, 2023 7.1100 7.3300 6.5500 6.5600 6.5600 54,000
Jan 31, 2023 7.4100 7.5800 6.8600 7.2400 7.2400 176,500
Jan 30, 2023 8.1400 8.1400 7.5200 7.8000 7.8000 16,400
Jan 27, 2023 8.4100 8.4100 7.6500 7.8700 7.8700 32,400
Jan 26, 2023 7.6400 8.4060 7.6000 8.1700 8.1700 44,600
Jan 25, 2023 7.4100 7.7500 7.3700 7.5600 7.5600 31,400
Jan 24, 2023 7.4900 7.7500 7.4000 7.5700 7.5700 29,500
Jan 23, 2023 7.5400 7.7500 7.3900 7.6700 7.6700 27,600
Jan 20, 2023 7.1800 7.7500 7.1100 7.6800 7.6800 14,900
Jan 19, 2023 7.2200 7.4800 7.2000 7.2000 7.2000 8,900
Jan 18, 2023 8.1700 8.3200 7.2900 7.3000 7.3000 29,300
Jan 17, 2023 8.3800 8.5400 7.8200 8.0500 8.0500 40,000
Jan 13, 2023 7.8100 9.1100 7.8100 8.7200 8.7200 105,300
Jan 12, 2023 7.6100 8.2000 7.6100 7.9500 7.9500 23,300
Jan 11, 2023 7.5800 8.1800 7.5800 8.0100 8.0100 38,900
Jan 10, 2023 7.4200 8.2760 7.1800 7.8100 7.8100 115,600
Jan 09, 2023 7.5100 7.6700 7.2700 7.5600 7.5600 75,100
Jan 06, 2023 7.1500 8.1700 7.0800 7.2600 7.2600 152,000
Jan 05, 2023 9.0600 9.0600 7.2600 7.5300 7.5300 211,900
Jan 04, 2023 12.3300 13.4500 8.9000 8.9000 8.9000 886,800
Jan 03, 2023 9.6600 20.6300 9.4500 15.6600 15.6600 12,363,90
MATTHEW NACHTRAB REPORTS 27.7% STAKE IN RESHAPE LIFESCIENCES AS
NACHTRAB-PURCHASED CO'S COMMON STOCK BASED ON BELIEF THAT SUCH SECURITIES, AT CURRENT MARKET PRICES, REPRESENTED AN ATTRACTIVE INVESTMENT OPPORTUNITY
NACHTRAB - WROTE A LETTER TO THE CEO OF CO WITH RECOMMENDATIONS FOR THE MANAGEMENT TEAM’S STRATEGY GOING FORWARD
https://ir.reshapelifesciences.com/static-files/aa8a67f3-70fe-4b27-aa86-95ba8c3ce91a
I am excited for your new tenure as CEO of ReShape Lifesciences and I believe your team can rebuild and create a $100m plus market cap company with some austerity measures, leveraging assets currently owned, and capitalizing on the medicated weight loss secular trend to generate lead flow and massive revenue growth. I am willing to discuss this and advise in any way I can help.
very low free float: 442.49k
Estimated share price by March 20, 2024.
2023-03-20 2024-03-20 High 52.50 Average 39.52 Low 27.78
Wish: 0.3269-0.0886 (-21.32%)
Last 2 months:
Apr 11, 2023 0.4160 0.4300 0.3100 0.3270 0.3270 74,793,200
Apr 10, 2023 0.4000 0.4320 0.3980 0.4160 0.4160 18,978,100
Apr 06, 2023 0.3900 0.4160 0.3760 0.4100 0.4100 13,455,700
Apr 05, 2023 0.4030 0.4040 0.3810 0.3870 0.3870 14,607,000
Apr 04, 2023 0.4230 0.4290 0.3950 0.4050 0.4050 14,377,500
Apr 03, 2023 0.4380 0.4460 0.4090 0.4230 0.4230 18,779,100
Mar 31, 2023 0.3980 0.4490 0.3950 0.4460 0.4460 36,293,800
Mar 30, 2023 0.4100 0.4190 0.3910 0.3920 0.3920 17,616,800
Mar 29, 2023 0.3750 0.4050 0.3750 0.3990 0.3990 18,096,200
Mar 28, 2023 0.3730 0.3850 0.3650 0.3740 0.3740 15,095,100
Mar 27, 2023 0.3960 0.3970 0.3610 0.3770 0.3770 20,973,400
Mar 24, 2023 0.3900 0.4000 0.3830 0.3870 0.3870 17,566,200
Mar 23, 2023 0.4000 0.4230 0.3900 0.3970 0.3970 18,709,300
Mar 22, 2023 0.4100 0.4170 0.3870 0.3900 0.3900 22,647,000
Mar 21, 2023 0.4000 0.4190 0.3970 0.4100 0.4100 21,568,800
Mar 20, 2023 0.3960 0.4300 0.3810 0.3920 0.3920 29,845,000
Mar 17, 2023 0.4000 0.4100 0.3750 0.3980 0.3980 67,584,700
Mar 16, 2023 0.4050 0.4280 0.3850 0.4080 0.4080 29,986,700
Mar 15, 2023 0.4100 0.4170 0.3910 0.4020 0.4020 20,271,400
Mar 14, 2023 0.4380 0.4490 0.4120 0.4160 0.4160 25,739,500
Mar 13, 2023 0.4030 0.4390 0.3800 0.4200 0.4200 34,898,400
Mar 10, 2023 0.4300 0.4330 0.3960 0.4110 0.4110 42,152,600
Mar 09, 2023 0.4590 0.4650 0.4300 0.4300 0.4300 31,791,300
Mar 08, 2023 0.4780 0.4800 0.4510 0.4550 0.4550 29,756,000
Mar 07, 2023 0.4980 0.5000 0.4780 0.4790 0.4790 21,337,300
Mar 06, 2023 0.5130 0.5200 0.4830 0.4920 0.4920 24,015,700
Mar 03, 2023 0.4800 0.5240 0.4800 0.5040 0.5040 33,997,400
Mar 02, 2023 0.4560 0.5050 0.4500 0.4770 0.4770 38,321,700
Mar 01, 2023 0.4890 0.4940 0.4600 0.4610 0.4610 33,428,600
Feb 28, 2023 0.4900 0.5400 0.4750 0.4870 0.4870 42,315,600
Feb 27, 2023 0.5220 0.5230 0.5000 0.5010 0.5010 34,319,000
Feb 24, 2023 0.6370 0.6500 0.5000 0.5100 0.5100 78,666,900
Feb 23, 2023 0.7200 0.7350 0.6610 0.7150 0.7150 42,283,000
Feb 22, 2023 0.6800 0.7150 0.6550 0.7120 0.7120 43,203,300
Feb 21, 2023 0.7500 0.7760 0.6670 0.6670 0.6670 48,835,500
Feb 17, 2023 0.8350 0.8390 0.7120 0.7540 0.7540 56,366,900
Feb 16, 2023 0.8600 0.9690 0.8250 0.8400 0.8400 61,801,700
Feb 15, 2023 0.7500 0.9700 0.7430 0.9450 0.9450 84,528,000
Feb 14, 2023 0.9000 0.9400 0.7410 0.7500 0.7500 81,784,000
Feb 13, 2023 0.6720 1.0700 0.6200 0.8790 0.8790 175,126,700
marketcap is 1/3 of the cash.
Wish: 0.3269-0.0886 (-21.32%)
Last 2 months:
Apr 11, 2023 0.4160 0.4300 0.3100 0.3270 0.3270 74,793,200
Apr 10, 2023 0.4000 0.4320 0.3980 0.4160 0.4160 18,978,100
Apr 06, 2023 0.3900 0.4160 0.3760 0.4100 0.4100 13,455,700
Apr 05, 2023 0.4030 0.4040 0.3810 0.3870 0.3870 14,607,000
Apr 04, 2023 0.4230 0.4290 0.3950 0.4050 0.4050 14,377,500
Apr 03, 2023 0.4380 0.4460 0.4090 0.4230 0.4230 18,779,100
Mar 31, 2023 0.3980 0.4490 0.3950 0.4460 0.4460 36,293,800
Mar 30, 2023 0.4100 0.4190 0.3910 0.3920 0.3920 17,616,800
Mar 29, 2023 0.3750 0.4050 0.3750 0.3990 0.3990 18,096,200
Mar 28, 2023 0.3730 0.3850 0.3650 0.3740 0.3740 15,095,100
Mar 27, 2023 0.3960 0.3970 0.3610 0.3770 0.3770 20,973,400
Mar 24, 2023 0.3900 0.4000 0.3830 0.3870 0.3870 17,566,200
Mar 23, 2023 0.4000 0.4230 0.3900 0.3970 0.3970 18,709,300
Mar 22, 2023 0.4100 0.4170 0.3870 0.3900 0.3900 22,647,000
Mar 21, 2023 0.4000 0.4190 0.3970 0.4100 0.4100 21,568,800
Mar 20, 2023 0.3960 0.4300 0.3810 0.3920 0.3920 29,845,000
Mar 17, 2023 0.4000 0.4100 0.3750 0.3980 0.3980 67,584,700
Mar 16, 2023 0.4050 0.4280 0.3850 0.4080 0.4080 29,986,700
Mar 15, 2023 0.4100 0.4170 0.3910 0.4020 0.4020 20,271,400
Mar 14, 2023 0.4380 0.4490 0.4120 0.4160 0.4160 25,739,500
Mar 13, 2023 0.4030 0.4390 0.3800 0.4200 0.4200 34,898,400
Mar 10, 2023 0.4300 0.4330 0.3960 0.4110 0.4110 42,152,600
Mar 09, 2023 0.4590 0.4650 0.4300 0.4300 0.4300 31,791,300
Mar 08, 2023 0.4780 0.4800 0.4510 0.4550 0.4550 29,756,000
Mar 07, 2023 0.4980 0.5000 0.4780 0.4790 0.4790 21,337,300
Mar 06, 2023 0.5130 0.5200 0.4830 0.4920 0.4920 24,015,700
Mar 03, 2023 0.4800 0.5240 0.4800 0.5040 0.5040 33,997,400
Mar 02, 2023 0.4560 0.5050 0.4500 0.4770 0.4770 38,321,700
Mar 01, 2023 0.4890 0.4940 0.4600 0.4610 0.4610 33,428,600
Feb 28, 2023 0.4900 0.5400 0.4750 0.4870 0.4870 42,315,600
Feb 27, 2023 0.5220 0.5230 0.5000 0.5010 0.5010 34,319,000
Feb 24, 2023 0.6370 0.6500 0.5000 0.5100 0.5100 78,666,900
Feb 23, 2023 0.7200 0.7350 0.6610 0.7150 0.7150 42,283,000
Feb 22, 2023 0.6800 0.7150 0.6550 0.7120 0.7120 43,203,300
Feb 21, 2023 0.7500 0.7760 0.6670 0.6670 0.6670 48,835,500
Feb 17, 2023 0.8350 0.8390 0.7120 0.7540 0.7540 56,366,900
Feb 16, 2023 0.8600 0.9690 0.8250 0.8400 0.8400 61,801,700
Feb 15, 2023 0.7500 0.9700 0.7430 0.9450 0.9450 84,528,000
Feb 14, 2023 0.9000 0.9400 0.7410 0.7500 0.7500 81,784,000
Feb 13, 2023 0.6720 1.0700 0.6200 0.8790 0.8790 175,126,700
marketcap is 1/3 of the cash.
LCI: 0.7601
Shares Outstanding 10.77M
Float 8.39M
Time for recovery?? Down with low volume.
Apr 11, 2023 0.9400 0.9400 0.7601 0.7601 0.7601 146,646
Apr 10, 2023 0.9750 0.9800 0.9070 0.9180 0.9180 31,000
Apr 03, 2023 1.6800 1.8900 0.8600 0.9210 0.9210 1,393,300
Mar 27, 2023 1.5700 1.7400 1.5400 1.7400 1.7400 119,300
Mar 20, 2023 1.6500 1.8200 1.5600 1.5900 1.5900 190,800
Mar 13, 2023 1.8600 1.9500 1.6000 1.6500 1.6500 422,900
Mar 06, 2023 2.1800 2.2000 1.8500 1.9000 1.9000 171,200
Feb 27, 2023 2.1700 2.2600 2.0600 2.1400 2.1400 136,300
Feb 20, 2023 2.2400 2.4400 2.0300 2.1600 2.1600 396,000
Feb 13, 2023 2.7500 2.7990 2.4500 2.4800 2.4800 295,800
Feb 06, 2023 2.7200 3.2500 2.4040 2.7500 2.7500 567,125
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's product portfolio includes Amphetamine IR tablets, Amphetamine ER capsules, Dicyclomine tablets, Fluphenazine tablets, Levothyroxine capsules, Methylphenidate CD capsules, Methylphenidate ER, Posaconazole DR tablets, Probenecid tablets, and Verapamil SR tablets, as well as Numbrino nasal solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, Sinotherapeutics, Respirent Pharmaceuticals Co., Ltd., HEC Pharm Group, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.
LCI: 0.7601
Shares Outstanding 10.77M
Float 8.39M
Time for recovery?? Down with low volume.
Apr 11, 2023 0.9400 0.9400 0.7601 0.7601 0.7601 146,646
Apr 10, 2023 0.9750 0.9800 0.9070 0.9180 0.9180 31,000
Apr 03, 2023 1.6800 1.8900 0.8600 0.9210 0.9210 1,393,300
Mar 27, 2023 1.5700 1.7400 1.5400 1.7400 1.7400 119,300
Mar 20, 2023 1.6500 1.8200 1.5600 1.5900 1.5900 190,800
Mar 13, 2023 1.8600 1.9500 1.6000 1.6500 1.6500 422,900
Mar 06, 2023 2.1800 2.2000 1.8500 1.9000 1.9000 171,200
Feb 27, 2023 2.1700 2.2600 2.0600 2.1400 2.1400 136,300
Feb 20, 2023 2.2400 2.4400 2.0300 2.1600 2.1600 396,000
Feb 13, 2023 2.7500 2.7990 2.4500 2.4800 2.4800 295,800
Feb 06, 2023 2.7200 3.2500 2.4040 2.7500 2.7500 567,125
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's product portfolio includes Amphetamine IR tablets, Amphetamine ER capsules, Dicyclomine tablets, Fluphenazine tablets, Levothyroxine capsules, Methylphenidate CD capsules, Methylphenidate ER, Posaconazole DR tablets, Probenecid tablets, and Verapamil SR tablets, as well as Numbrino nasal solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, Sinotherapeutics, Respirent Pharmaceuticals Co., Ltd., HEC Pharm Group, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.
RSLS: 3,5199 +32,83%
52w: 2.49 - 61.45
SAN CLEMENTE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 16/792,094, entitled, “Systems and Methods for Determining Failure of Intragastric Devices,” related to its Obalon® Balloon System. The patent will cover additional claims for the Obalon® Balloon System and is expected to provide protection into at least January 2031, without accounting for a potential Patent Term Extension (PTE).
“Allowance of this patent significantly strengthens our intellectual property portfolio around innovations for the Obalon Intragastric Balloon System,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. “Since filing our first patent application in 2011, ReShape has pioneered the field, amassing a patent family around the intragastric balloon system, supported by a variety of novel, pending and protected inventions. Going forward, we will continue to build a defensive ‘moat’ around our product portfolio and commercialization efforts, while also taking offensive action to defend our patent position, when necessary.”
About ReShape Lifesciences™
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. ReShapeCare™ is a virtual weight-management program that supports lifestyle changes for all weight loss patients led by board-certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of Type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
RSLS: 3,5199 +32,83%
52w: 2.49 - 61.45
SAN CLEMENTE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 16/792,094, entitled, “Systems and Methods for Determining Failure of Intragastric Devices,” related to its Obalon® Balloon System. The patent will cover additional claims for the Obalon® Balloon System and is expected to provide protection into at least January 2031, without accounting for a potential Patent Term Extension (PTE).
“Allowance of this patent significantly strengthens our intellectual property portfolio around innovations for the Obalon Intragastric Balloon System,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. “Since filing our first patent application in 2011, ReShape has pioneered the field, amassing a patent family around the intragastric balloon system, supported by a variety of novel, pending and protected inventions. Going forward, we will continue to build a defensive ‘moat’ around our product portfolio and commercialization efforts, while also taking offensive action to defend our patent position, when necessary.”
About ReShape Lifesciences™
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. ReShapeCare™ is a virtual weight-management program that supports lifestyle changes for all weight loss patients led by board-certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of Type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
Wish: 0.3201
52w: 0.316 – 2.28
we see anover reaction
The 1-for-30 reverse stock split will automatically convert 30 shares of the Company’s common stock into one new share of common stock. No fractional shares will be issued in connection with the reverse stock split. Stockholders of common stock otherwise entitled to a fractional share as a result of the reverse stock split will automatically be entitled to receive an additional fraction of a share of common stock to round up to the next whole share. The reverse split will reduce the number of shares of outstanding common stock from approximately 695,000,000 shares to approximately 23,170,000 shares. Additionally, outstanding equity-based awards and other outstanding equity rights will be proportionately adjusted.
Total Cash (mrq) 719M
Total Cash Per Share (mrq) 1.03
Total Debt (mrq) 20M
Wish: 0.3201
52w: 0.316 – 2.28
we see anover reaction
The 1-for-30 reverse stock split will automatically convert 30 shares of the Company’s common stock into one new share of common stock. No fractional shares will be issued in connection with the reverse stock split. Stockholders of common stock otherwise entitled to a fractional share as a result of the reverse stock split will automatically be entitled to receive an additional fraction of a share of common stock to round up to the next whole share. The reverse split will reduce the number of shares of outstanding common stock from approximately 695,000,000 shares to approximately 23,170,000 shares. Additionally, outstanding equity-based awards and other outstanding equity rights will be proportionately adjusted.
Total Cash (mrq) 719M
Total Cash Per Share (mrq) 1.03
Total Debt (mrq) 20M
French regulators lift ban on online marketplace Wish.
Wish partners with shipsage to provide faster order fulfillment for US merchants.
QBAN: 0.0032
145.187.881 shares
= marketcap: $464.000
Total assets 1,094,437
https://www.telcocuba.com/
Telco Cuba, Inc. is a technology solutions service provider, which offers services under the brand name Amgentech and Telco Cuba. The Company offers telecommunication services and equipment, including mobile phones, mobile voice service, voice over Internet protocol (VoIP) service, and calling cards. The Company intends to offer prepaid service/plans that include predefined minute/unlimited minute plans. Under the brand name Telco Cuba, the Company is targeting the Cuban American demographic in the United States. Under the brand name Amgentech, the Company offers technology solutions, which include but are not limited to software and network architecture services, software development, Website development, hosting and colocation services, managed network and managed server services, voice over Internet protocol (IP) servers and bulk mailing services.
Advanced Satellite Systems, Inc. provides Internet service in speed increments of 5, 25, 50, and 100MB/s.
VoIP telephone service is provided with unlimited calling to the US, Canada, and Mexico. Service to other
countries is metered at predefined rates. Cable television service is provided in increments of 25, 50, and 100
channels and forthcoming will be offered via an IPTV infrastructure offering basic service of 103 channels,
expanded service with an additional 35 channels, and premium channels offered on an a la cart basis.
Under the brand name “Amgentech”, the company offers best of breed technology solutions which include, but
are not limited to Software and Network architecture services, software development, web site development,
hosting and colocation services, managed network and managed server services, voice over ip servers and
bulk mailing services. Amgentech has been providing services since 2001, building out networks and services
in the international markets of Colombia, Costa Rica, and Panama.
Amgentech, Inc. is a Florida based Corporation engaged in the business of providing technology solutions,
integrating and building technology infrastructure and software and website development. Amgentech, Inc. also
offers managed collocated and leased servers. Originally founded in 2001, Amgentech, Inc. has been providing
Internet based solutions, VoIP infrastructure and consulting services for over 20 years to diverse clients in The
United States of America, the countries of Colombia, Costa Rica, El Salvador, Nicaragua, Panama, and
Venezuela. Amgentech, Inc. continues to provide these same services, in addition to providing the technical
and Internet know how to implement the technological vision that is envisioned for Solidus Communications,
Inc., Amgentech will be the sole technical services provider.
QBAN: 0.0032
145.187.881 shares
= marketcap: $464.000
Total assets 1,094,437
https://www.telcocuba.com/
Telco Cuba, Inc. is a technology solutions service provider, which offers services under the brand name Amgentech and Telco Cuba. The Company offers telecommunication services and equipment, including mobile phones, mobile voice service, voice over Internet protocol (VoIP) service, and calling cards. The Company intends to offer prepaid service/plans that include predefined minute/unlimited minute plans. Under the brand name Telco Cuba, the Company is targeting the Cuban American demographic in the United States. Under the brand name Amgentech, the Company offers technology solutions, which include but are not limited to software and network architecture services, software development, Website development, hosting and colocation services, managed network and managed server services, voice over Internet protocol (IP) servers and bulk mailing services.
Advanced Satellite Systems, Inc. provides Internet service in speed increments of 5, 25, 50, and 100MB/s.
VoIP telephone service is provided with unlimited calling to the US, Canada, and Mexico. Service to other
countries is metered at predefined rates. Cable television service is provided in increments of 25, 50, and 100
channels and forthcoming will be offered via an IPTV infrastructure offering basic service of 103 channels,
expanded service with an additional 35 channels, and premium channels offered on an a la cart basis.
Under the brand name “Amgentech”, the company offers best of breed technology solutions which include, but
are not limited to Software and Network architecture services, software development, web site development,
hosting and colocation services, managed network and managed server services, voice over ip servers and
bulk mailing services. Amgentech has been providing services since 2001, building out networks and services
in the international markets of Colombia, Costa Rica, and Panama.
Amgentech, Inc. is a Florida based Corporation engaged in the business of providing technology solutions,
integrating and building technology infrastructure and software and website development. Amgentech, Inc. also
offers managed collocated and leased servers. Originally founded in 2001, Amgentech, Inc. has been providing
Internet based solutions, VoIP infrastructure and consulting services for over 20 years to diverse clients in The
United States of America, the countries of Colombia, Costa Rica, El Salvador, Nicaragua, Panama, and
Venezuela. Amgentech, Inc. continues to provide these same services, in addition to providing the technical
and Internet know how to implement the technological vision that is envisioned for Solidus Communications,
Inc., Amgentech will be the sole technical services provider.
QBAN: 0.0002
52w: 0.0002 – 0.0009
2 years: 0.0002 – 0.0018
https://www.telcocuba.com/
Telco Cuba, Inc. is a technology solutions service provider, which offers services under the brand name Amgentech and Telco Cuba. The Company offers telecommunication services and equipment, including mobile phones, mobile voice service, voice over Internet protocol (VoIP) service, and calling cards. The Company intends to offer prepaid service/plans that include predefined minute/unlimited minute plans. Under the brand name Telco Cuba, the Company is targeting the Cuban American demographic in the United States. Under the brand name Amgentech, the Company offers technology solutions, which include but are not limited to software and network architecture services, software development, Website development, hosting and colocation services, managed network and managed server services, voice over Internet protocol (IP) servers and bulk mailing services.
NO DILUTION
The company has authorized the issuance of 7,999,000,000 of which 7,259,394,066 have been issued as of 02/28/2023. Each common share is entitled to vote on all matters submitted to a vote of the holders of the company
7,259,394,066 as of 11/30/2022
7,259,394,066 as of 11/30/2021
7,259,394,066 as of 02/28/2021
Advanced Satellite Systems, Inc. provides Internet service in speed increments of 5, 25, 50, and 100MB/s.
VoIP telephone service is provided with unlimited calling to the US, Canada, and Mexico. Service to other
countries is metered at predefined rates. Cable television service is provided in increments of 25, 50, and 100
channels and forthcoming will be offered via an IPTV infrastructure offering basic service of 103 channels,
expanded service with an additional 35 channels, and premium channels offered on an a la cart basis.
Under the brand name “Amgentech”, the company offers best of breed technology solutions which include, but
are not limited to Software and Network architecture services, software development, web site development,
hosting and colocation services, managed network and managed server services, voice over ip servers and
bulk mailing services. Amgentech has been providing services since 2001, building out networks and services
in the international markets of Colombia, Costa Rica, and Panama.
Amgentech, Inc. is a Florida based Corporation engaged in the business of providing technology solutions,
integrating and building technology infrastructure and software and website development. Amgentech, Inc. also
offers managed collocated and leased servers. Originally founded in 2001, Amgentech, Inc. has been providing
Internet based solutions, VoIP infrastructure and consulting services for over 20 years to diverse clients in The
United States of America, the countries of Colombia, Costa Rica, El Salvador, Nicaragua, Panama, and
Venezuela. Amgentech, Inc. continues to provide these same services, in addition to providing the technical
and Internet know how to implement the technological vision that is envisioned for Solidus Communications,
Inc., Amgentech will be the sole technical services provider.
QBAN: 0.0002
52w: 0.0002 – 0.0009
2 years: 0.0002 – 0.0018
https://www.telcocuba.com/
Telco Cuba, Inc. is a technology solutions service provider, which offers services under the brand name Amgentech and Telco Cuba. The Company offers telecommunication services and equipment, including mobile phones, mobile voice service, voice over Internet protocol (VoIP) service, and calling cards. The Company intends to offer prepaid service/plans that include predefined minute/unlimited minute plans. Under the brand name Telco Cuba, the Company is targeting the Cuban American demographic in the United States. Under the brand name Amgentech, the Company offers technology solutions, which include but are not limited to software and network architecture services, software development, Website development, hosting and colocation services, managed network and managed server services, voice over Internet protocol (IP) servers and bulk mailing services.
NO DILUTION
The company has authorized the issuance of 7,999,000,000 of which 7,259,394,066 have been issued as of 02/28/2023. Each common share is entitled to vote on all matters submitted to a vote of the holders of the company
7,259,394,066 as of 11/30/2022
7,259,394,066 as of 11/30/2021
7,259,394,066 as of 02/28/2021
Advanced Satellite Systems, Inc. provides Internet service in speed increments of 5, 25, 50, and 100MB/s.
VoIP telephone service is provided with unlimited calling to the US, Canada, and Mexico. Service to other
countries is metered at predefined rates. Cable television service is provided in increments of 25, 50, and 100
channels and forthcoming will be offered via an IPTV infrastructure offering basic service of 103 channels,
expanded service with an additional 35 channels, and premium channels offered on an a la cart basis.
Under the brand name “Amgentech”, the company offers best of breed technology solutions which include, but
are not limited to Software and Network architecture services, software development, web site development,
hosting and colocation services, managed network and managed server services, voice over ip servers and
bulk mailing services. Amgentech has been providing services since 2001, building out networks and services
in the international markets of Colombia, Costa Rica, and Panama.
Amgentech, Inc. is a Florida based Corporation engaged in the business of providing technology solutions,
integrating and building technology infrastructure and software and website development. Amgentech, Inc. also
offers managed collocated and leased servers. Originally founded in 2001, Amgentech, Inc. has been providing
Internet based solutions, VoIP infrastructure and consulting services for over 20 years to diverse clients in The
United States of America, the countries of Colombia, Costa Rica, El Salvador, Nicaragua, Panama, and
Venezuela. Amgentech, Inc. continues to provide these same services, in addition to providing the technical
and Internet know how to implement the technological vision that is envisioned for Solidus Communications,
Inc., Amgentech will be the sole technical services provider.
jagx: 1.13
52w: 0.73 - 61.125
Jaguar Health Reports 2022 Financial Results – Prescription Revenues up 179% to $11.9 Million
Prescription product net revenue was approximately $11.9 million for the year ended December 31, 2022 versus approximately $4.3 million for the year ended December 31, 2021, an increase of 178.7%.
Prescription product net revenue of approximately $3.3 million in Q4 2022 increased 3.4% over Q3 2022 and increased approximately 57% over prescription product net revenue in Q4 2021.
As of March 24, 2023, the filing date of Jaguar’s annual report on Form 10-K for the year 2022, the Company’s cash position was approximately $15.3 million.
Core initiatives:
Patient enrollment in OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) is now at approximately 80% and expected to complete in Q2 2023.
Jaguar planning to support investigator-initiated proof-of-concept (POC) studies of crofelemer in 2023 for short bowel syndrome (SBS) with intestinal failure and congenital diarrheal disorders (CDD). POC targeted for 2H 2023 in support of potential early patient access in Europe, potentially in 2024.
The Company plans to submit an Investigational New Drug (IND) application in Q2 2023 to FDA for crofelemer for microvillus inclusion disease, a rare CDD condition, for which Orphan Drug Designation has been granted by both the FDA and European Medicines Agency.
SAN FRANCISCO, CA / March 27, 2023 / Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”) today provided Company updates and reported consolidated financial results for the year ended December 31, 2022.
The combined net revenue for Mytesi® and the Company’s other crofelemer prescription product, Canalevia®-CA1, which became commercially available in April 2022, was approximately $11.9 million in the year 2022, representing an increase of 178.7% over the combined net revenue in the year 2021, which totaled $4.3 million. The combined net revenue for Mytesi and Canalevia-CA1 was approximately $3.3 million in the fourth quarter of 2022, representing an increase of 3.4% over prescription product net revenue in the third quarter of 2022, which totaled approximately $3.1 million, and an increase of approximately 57.0% over prescription product net revenue in the fourth quarter of 2021, which totaled approximately $2.1 million.
“We are very pleased that growth in Mytesi revenue continued for the sixth quarter in a row in the fourth quarter of 2022,” said Lisa Conte, Jaguar's president and CEO. “As previously announced, the transition we completed throughout the end of 2021 and into the beginning of 2022 to a limited distribution network of specialty pharmacies resulted in a meaningful reduction in Mytesi distribution costs as well as a higher average net price. It is wonderful to see Mytesi continuing to grow following this transition and the successful implementation of our Mytesi patient access programs, including our ongoing disease state education and promotional activities. Most importantly, we are pleased with the realization of our mission of providing relief with a novel, plant-based, first-in-class mechanism of action to patients in need – including patients for whom no alternative therapeutic options exist.”
“As I frequently state, what is really powerful about crofelemer is that it is a pipeline within a product. Our key near-term clinical activity is our Phase 3 pivotal OnTarget trial of our novel botanical drug, crofelemer, for our core follow-on indication of prophylaxis of cancer therapy-related diarrhea (CTD). Our efforts over the past year to expand the OnTarget trial to new U.S. and international sites – with trial sites now active in Eastern Europe – in both Georgia and the Republic of Serbia – as well as in Argentina and Taiwan – have significantly accelerated patient enrollment. As announced, enrollment reached approximately 75% one month ago. Enrollment is now at approximately 80%, and target trial enrollment of 256 patients is expected to complete in the second quarter of 2023, which is just around the corner,” Conte said.
The Company’s second prioritized clinical program centers around our approved investigator-initiated proof-of-concept trial of crofelemer for short bowel syndrome with intestinal failure (SBS-IF) and for microvillus inclusion disease (MVID), a rare congenital diarrheal disorder (CDD). SBS-IF and MVID are devastating and often catastrophic diseases for patients, who are frequently on parenteral nutrition for as long as 20 hours a day, seven days a week. Jaguar and the company it established in Europe, Napo Therapeutics, are planning to support investigator-initiated proof-of-concept studies of crofelemer in patients with SBS-IF or MVID, focused on obtaining proof-of-concept (POC) of reduction of requirements of parenteral support including parenteral nutrition and/or intravenous fluids, in 2023. In accordance with the guidelines of specific European Union countries, publications of POC data from these trials could support early patient access to crofelemer for SBS-IF or MVID through programs in Europe. Early access programs are revenue generating, and reimbursable for participating patients.
COMPANY MILESTONES, UPDATES & ACCOMPLISHMENTS:
As of March 24, 2022, the filing date of Jaguar’s annual report on Form 10-K for the year 2022, the Company’s cash position was approximately $ 15.3 million.
Phase 3 clinical trial of crofelemer for cancer therapy-related diarrhea (CTD) in humans: The pivotal OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy, with or without chemotherapy, was initiated in October 2020 and is ongoing. The trial is evaluating the effectiveness of crofelemer's novel mechanism of action – the modulation of two chloride ion channels in the gastrointestinal tract – to mitigate or substantially reduce chronic cancer therapy-related diarrhea. Jaguar’s expectation is that this placebo-controlled trial will provide evidence that diarrhea associated with targeted cancer therapies is chronic, not acute, and impacts the patient's ability to remain on their cancer therapy regimens at proven doses for better outcomes. Each year, according to the CDC, more than 1 million cancer patients receive chemotherapy or radiation in an outpatient oncology clinic in the U.S. Treatment can last for months to years, in both the curative and metastatic situations. Crofelemer is currently approved for a chronic use in HIV/AIDS patients, providing a potential opportunity for a paradigm shift for prophylaxis of CTD compared to the management of severe chronic diarrhea with constipating agents such as antimotility drugs, which are predominantly opioids.
February 2023: FDA granted Orphan Drug Designation for crofelemer for Microvillus Inclusion Disease (MVID), a second rare disease indication: As announced, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to crofelemer for the indication of microvillus inclusion disease (MVID), a rare congenital diarrheal disorder (CDD), following review of the ODD application the Company submitted to the FDA. Crofelemer is a new molecular entity that now holds four orphan designations, as crofelemer previously received ODD for MVID from the European Medicines Agency (EMA) and for short bowel syndrome (SBS) from both the FDA and the EMA. Jaguar is planning to support investigator-initiated proof-of-concept studies of crofelemer in patients with SBS-IF or MVID, focused on obtaining proof-of-concept (POC) of reduction of requirements of parenteral support including parenteral nutrition and/or intravenous fluids, in 2023. SBS and CDD are the initial focus of Napo Therapeutics, the Italian corporation established by Jaguar in Milan, Italy in 2021 with a mission to expand crofelemer access in Europe for the treatment and management of orphan and rare disease indications. In accordance with the guidelines of specific European Union countries, publications of POC data from these trials could support early patient access to crofelemer for SBS-IF or MVID through programs in Europe, potentially in 2024. Early access programs are revenue generating, and reimbursable for participating patients.
Q2 2023 Milestone: Submit Investigational New Drug (IND) application to FDA for MVID: As announced, the Company intends to submit an IND application to FDA in the second quarter of 2023 for crofelemer for this ultra-rare CDD condition.
January 2023: Jaguar and Filament Health, with Funding from One Small Planet, Formed Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses: The focus of U.S.-based joint venture Magdalena Biosciences, Inc. is to develop novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (ADHD) in adults. The goal of the collaboration is to extend the botanical drug development capabilities of Jaguar and Filament in order to develop pharmaceutical-grade, standardized drug candidates for mental health disorders, and to partner with a potential future licensee to develop and commercialize these novel plant-based drugs.
September 2022: The Company announced activation by the FDA of IND application for NP-300, a novel drug candidate for the symptomatic relief and treatment of diarrhea from cholera and other pathogens: The Company plans to conduct a phase 1 trial in healthy volunteers, and following the completion of the phase 1 trial, the Company will be positioned to initiate the next stage of its clinical development program for cholera-related diarrhea when the Company’s development team has the requisite resources and bandwidth to initiate the additional required trials. The Company is grateful for the partial financial support from the National Institute of Allergy and Infectious Diseases (NIAID) to support the NP-300 preclinical program. NP-300 is a novel oral botanical drug product that is sustainably derived from the Croton lechleri tree, the same source as that for crofelemer, and is planned to be developed under the FDA's Botanical Guidance. As stated on the FDA's website, crofelemer is currently one of only two drugs that have been approved under the FDA's Botanical Guidance definition of a botanical drug product. Upon completion of the requisite development activities to support the New Drug Application (NDA) and subsequent approval of NP-300 by the FDA for the symptomatic relief and treatment of diarrhea from cholera, the Company intends to pursue a Tropical Disease Priority Review Voucher to develop NP-300 for this indication under the FDA's financial incentive program. Priority review vouchers are transferable, and in past transactions by other companies have sold for values ranging from $67 million to $350 million, which provides for a potential immediate return on investment upon approval of NP-300 for the cholera-related diarrhea indication.
Other investigator-initiated trials of crofelemer:
Currently ongoing: Study of chronic idiopathic diarrhea in non-HIV adult patients
Study Name: Yield of Diagnostic Tests and Management of Crofelemer for Chronic Idiopathic Diarrhea in Non-HIV Patients: A Pilot Study
Location: University of Texas Health Science Center at Houston
Currently ongoing: Study of functional diarrhea in non-HIV adult patients
Study Name: A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of crofelemer in subjects with functional diarrhea
Location: Beth Israel Deaconess Medical Center, a Harvard Medical School institution in Boston
COMPANY FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2022:
“As previously announced, the transition we completed in January 2022 to a limited distribution network of specialty pharmacies resulted in a meaningful reduction in Mytesi distribution costs as well as a higher average net price,” Ian Wendt, Jaguar's Chief Commercial Officer, stated. “I am very pleased to report that we significantly outperformed the industry gross-to-net average in the fourth quarter of 2022 – as we did in the four previous quarters – for sales of our human prescription product. This improvement in our gross-to-net was largely a result of the efficiencies realized by the transition to a closed network of specialty pharmacies. While Mytesi net revenue increased by 3.0% in the fourth quarter of 2022 over the third quarter of 2022, Mytesi total prescription volume decreased slightly by approximately 2% in this time period. This transition to specialty pharmacy distribution also assists in the preparation of the Company’s U.S. commercial distribution network for potential future indication expansion of crofelemer to other populations of patients with complex medical needs, such as CTD, inflammatory bowel disease, and SBS.”
The Company believes the availability of Mytesi through specialty pharmacies represents a significant benefit to patients, as such pharmacies focus on complex and chronic conditions and offer a higher level of support for prior authorizations, appeals, adherence reminders, counseling, and home delivery options.
Mytesi Prescription Volume: Mytesi total prescription volume was approximately 5,947 in the year 2022. Due to the transition to a limited distribution specialty pharmacy model in 2022, the Company cannot accurately compare prescription volume from 2021 to 2022, as there are significant differences in reporting methodology from these different distribution models. In the future, the Company will be able to accurately reflect growth in prescription volume using 2022 as the new baseline. Mytesi total prescription volume decreased slightly by approximately 2% in the fourth quarter of 2022 over the third quarter of 2022. Prescription volume differs from invoiced sales volume, which reflects, among other factors, varying buying patterns among specialty pharmacies in the closed network as they manage their inventory levels.
Net Mytesi Revenue: Net revenue for Mytesi was approximately $11.7 million in the year 2022, representing an increase of 174.8% over Mytesi net revenue in the year 2021, which totaled approximately $4.3 million. Mytesi net revenue was approximately $3.2 million in the fourth quarter of 2022, representing an increase of 3.0% over Mytesi net revenue in the third quarter of 2022, which totaled approximately $3.1 million, and an increase of approximately 55.8% over Mytesi net revenue in the fourth quarter of 2021, which totaled approximately $2.1 million.
The transition to a limited distribution network of specialty pharmacies, which was completed in January 2022, resulted in a meaningful reduction in Mytesi distribution costs and a higher average net price. As part of the process of transitioning to the closed specialty pharmacy network, the third and fourth quarters of 2021 were significantly impacted by the inventory draw-down of approximately 1,300 bottles of Mytesi across the Company’s third-party logistics warehouse, wholesalers, distributors, and retail stores.
Net Canalevia®-CA1 Revenue: Net revenue for the Company’s other crofelemer prescription product, Canalevia-CA1, which became commercially available in April 2022, was approximately $167 thousand in 2022. Canalevia-CA1 net revenue was approximately $24 thousand in the fourth quarter of 2022, representing an increase of 100% over Canalevia-CA1 net revenue in the third quarter of 2022, which totaled approximately $12 thousand.
Neonorm™: Revenues for the non-prescription Neonorm products were minimal for the fourth quarters of 2022 and 2021, in accordance with the Company’s primary focus on human health and prescription products.
Cost of Product Revenue: Total cost of product revenue for the year 2022 was $2.0 million compared to $2.3 million for the year 2021, representing a $0.3 million decrease year over year largely due to the reduction in distribution fees and decreased labor allocation in manufacturing.
Research and Development: The R&D expense increased by $2.6 million, from $15.1 million for the year 2021 to $17.7 million during the year 2022 largely due to increased clinical trial activities related to phase 3 CTD and other indications.
Sales and Marketing: The Sales and Marketing expense decreased slightly by $56 thousand from $8.9 million for the year 2021 to about the same in 2022. Direct marketing fees and expenses increased to expand market access to Mytesi through the Specialty Pharmacy channels but this was offset by the decrease in headcount.
General and Administrative: The G&A expense increased by $0.8 million, from $17.1 million for the year 2021 to $17.9 during the same quarter in 2022. The increase in expenses was largely due to an aggregate increase of $3.3 million in personnel and related benefits, public company expenses, rent, travel, and other expenses, offset by an aggregate decrease of $2.5 million in stock-based compensation, legal fees, consulting, and audit fees.
Loss from Operations: Loss from operations decreased by $6.3 million, from $40.7 million in the year 2021 to $34.4 million in 2022 largely due to the aggregate improvement in net revenue of $7.6 million, decreased cost of sales and marketing expenses of $0.4 million, and warrant inducement expenses of $1.6 million in 2021 and none recorded in 2022. These were offset by the aggregate increase in R&D and G&A expenses of $3.3 million.
Net Loss: Net loss attributable to common shareholders decreased by approximately $5.1 million, from $52.6 million in the year 2021 to $47.5 million in 2022. In addition to the loss from operations:
Interest expense increased by $4.3 million from $8.4 million in the year 2021 to $12.7 million in 2022 primarily due to additional interest expense incurred on royalty interest agreements primarily as result of the change in the timing of payments due to exchanges and a new royalty interest purchase agreement.
The loss on extinguishment of debt increased $1.4 million from $0.8 million for the year 2021 to $2.2 million in 2022 due to the extinguishment loss from the exchange of the outstanding balance of a royalty agreement for shares of the Company’s common stock.
Change in fair value of financial instrument and hybrid instrument designated at Fair Value Option (“FVO") decreased $1.9 million from a loss of approximately $2.0 million in the year 2021 to a loss of about $21,000 for the year 2022 primarily due to fair value adjustments in liability classified warrants and notes payable designated at FVO.
Other income (expenses) increased $1.7 million from approximately $0.8 million other expense for the year 2021 to approximately $1.0 million other income in 2022 due to write-off of extinguished liabilities as a result of legal release and reversal of long outstanding accruals with reasonable uncertainty to not be incurred.
Non-GAAP EBITDA: Non-GAAP EBITDA for the year 2022 and the year 2021 were a net loss of $28.1 million and net loss of $37.5 million, respectively.
Note Regarding Use of Non-GAAP Measures
The Company supplements its condensed consolidated financial statements presented on a GAAP basis by providing non-GAAP EBITDA and non-GAAP recurring EBITDA, which are considered non-GAAP under applicable SEC rules. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information that reflects the basis upon which Company management assesses and operates the business. These non-GAAP financial measures are not in accordance with GAAP and should not be viewed in isolation or as substitutes for GAAP net sales and GAAP net loss and are not substitutes for, or superior to, measures of financial performance in conformity with GAAP.
The Company defines non-GAAP EBITDA as net loss before interest expense and other expense, depreciation of property and equipment, amortization of intangible assets, share-based compensation expense and provision for or benefit from income taxes. The Company defines non-GAAP Recurring EBITDA as non-GAAP EBITDA adjusted for certain non-recurring revenues and expenses. Company management believes that non-GAAP EBITDA and non-GAAP Recurring EBITDA are meaningful indicators of Jaguar’s performance and provide useful information to investors regarding the Company’s results of operations and financial condition.
Participation Instructions for Webcast
When: Monday, March 27, 2023, at 8:00 AM Eastern Time
Participant Registration & Access Link: Click Here
Replay Instructions for Webcast
Replay of the webcast on the investor relations section of Jaguar’s website: (click here)
About Crofelemer
Crofelemer is the only oral FDA approved drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, Jaguar Health's wholly owned U.S. subsidiary, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities.
About Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics & Jaguar Animal Health
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, sustainably-derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Jaguar Health's wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human pharmaceuticals from plants harvested responsibly from rainforest areas. Our crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar Health is the majority shareholder of Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.), an Italian corporation established by Jaguar Health in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe. Jaguar Animal Health is a tradename of Jaguar Health.
For more information about Jaguar Health, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo Therapeutics, visit napotherapeutics.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the Company’s expectation that patient enrollment in the OnTarget trial will complete in Q2 2023, Jaguar’s expectation that the OnTarget trial will provide evidence that diarrhea associated with targeted cancer therapies is chronic, not acute, and impacts the patient's ability to remain on their cancer therapy regimens at proven doses for better outcomes, the Company’s expectation that crofelemer’s current approval for a chronic use in HIV/AIDS patients provides a potential opportunity for a paradigm shift for prophylaxis of CTD compared to the management of severe chronic diarrhea with constipating agents such as antimotility drugs, the expectation that Jaguar and Napo Therapeutics will support investigator-initiated proof-of-concept (POC) studies of crofelemer in 2023 for SBS with intestinal failure and congenital diarrheal disorders, the Company’s expectation that publications of data from these POC trials could support early patient access to crofelemer for SBS-IF or MVID through programs in Europe, potentially in 2024, the Company’s expectation that it will submit an IND application in Q2 2023 to FDA for crofelemer for MVID, the Company’s expectation that it will conduct a phase 1 trial of NP-300 in healthy volunteers, the Company’s expectation that NP-300 will be developed under the FDA's Botanical Guidance, the Company’s expectation that it will pursue a Tropical Disease Priority Review Voucher to develop NP-300, the Company’s expectation that it will in the future be able to accurately reflect growth in Mytesi prescription volume using 2022 as the new baseline, and the Company’s expectation that it will host an investor webcast on March 27, 2023. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Source: Jaguar Health, Inc.
Contact:
hello@jaguar.health
Jaguar-JAGX
jagx: 1.13
52w: 0.73 - 61.125
Jaguar Health Reports 2022 Financial Results – Prescription Revenues up 179% to $11.9 Million
Prescription product net revenue was approximately $11.9 million for the year ended December 31, 2022 versus approximately $4.3 million for the year ended December 31, 2021, an increase of 178.7%.
Prescription product net revenue of approximately $3.3 million in Q4 2022 increased 3.4% over Q3 2022 and increased approximately 57% over prescription product net revenue in Q4 2021.
As of March 24, 2023, the filing date of Jaguar’s annual report on Form 10-K for the year 2022, the Company’s cash position was approximately $15.3 million.
Core initiatives:
Patient enrollment in OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) is now at approximately 80% and expected to complete in Q2 2023.
Jaguar planning to support investigator-initiated proof-of-concept (POC) studies of crofelemer in 2023 for short bowel syndrome (SBS) with intestinal failure and congenital diarrheal disorders (CDD). POC targeted for 2H 2023 in support of potential early patient access in Europe, potentially in 2024.
The Company plans to submit an Investigational New Drug (IND) application in Q2 2023 to FDA for crofelemer for microvillus inclusion disease, a rare CDD condition, for which Orphan Drug Designation has been granted by both the FDA and European Medicines Agency.
SAN FRANCISCO, CA / March 27, 2023 / Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”) today provided Company updates and reported consolidated financial results for the year ended December 31, 2022.
The combined net revenue for Mytesi® and the Company’s other crofelemer prescription product, Canalevia®-CA1, which became commercially available in April 2022, was approximately $11.9 million in the year 2022, representing an increase of 178.7% over the combined net revenue in the year 2021, which totaled $4.3 million. The combined net revenue for Mytesi and Canalevia-CA1 was approximately $3.3 million in the fourth quarter of 2022, representing an increase of 3.4% over prescription product net revenue in the third quarter of 2022, which totaled approximately $3.1 million, and an increase of approximately 57.0% over prescription product net revenue in the fourth quarter of 2021, which totaled approximately $2.1 million.
“We are very pleased that growth in Mytesi revenue continued for the sixth quarter in a row in the fourth quarter of 2022,” said Lisa Conte, Jaguar's president and CEO. “As previously announced, the transition we completed throughout the end of 2021 and into the beginning of 2022 to a limited distribution network of specialty pharmacies resulted in a meaningful reduction in Mytesi distribution costs as well as a higher average net price. It is wonderful to see Mytesi continuing to grow following this transition and the successful implementation of our Mytesi patient access programs, including our ongoing disease state education and promotional activities. Most importantly, we are pleased with the realization of our mission of providing relief with a novel, plant-based, first-in-class mechanism of action to patients in need – including patients for whom no alternative therapeutic options exist.”
“As I frequently state, what is really powerful about crofelemer is that it is a pipeline within a product. Our key near-term clinical activity is our Phase 3 pivotal OnTarget trial of our novel botanical drug, crofelemer, for our core follow-on indication of prophylaxis of cancer therapy-related diarrhea (CTD). Our efforts over the past year to expand the OnTarget trial to new U.S. and international sites – with trial sites now active in Eastern Europe – in both Georgia and the Republic of Serbia – as well as in Argentina and Taiwan – have significantly accelerated patient enrollment. As announced, enrollment reached approximately 75% one month ago. Enrollment is now at approximately 80%, and target trial enrollment of 256 patients is expected to complete in the second quarter of 2023, which is just around the corner,” Conte said.
The Company’s second prioritized clinical program centers around our approved investigator-initiated proof-of-concept trial of crofelemer for short bowel syndrome with intestinal failure (SBS-IF) and for microvillus inclusion disease (MVID), a rare congenital diarrheal disorder (CDD). SBS-IF and MVID are devastating and often catastrophic diseases for patients, who are frequently on parenteral nutrition for as long as 20 hours a day, seven days a week. Jaguar and the company it established in Europe, Napo Therapeutics, are planning to support investigator-initiated proof-of-concept studies of crofelemer in patients with SBS-IF or MVID, focused on obtaining proof-of-concept (POC) of reduction of requirements of parenteral support including parenteral nutrition and/or intravenous fluids, in 2023. In accordance with the guidelines of specific European Union countries, publications of POC data from these trials could support early patient access to crofelemer for SBS-IF or MVID through programs in Europe. Early access programs are revenue generating, and reimbursable for participating patients.
COMPANY MILESTONES, UPDATES & ACCOMPLISHMENTS:
As of March 24, 2022, the filing date of Jaguar’s annual report on Form 10-K for the year 2022, the Company’s cash position was approximately $ 15.3 million.
Phase 3 clinical trial of crofelemer for cancer therapy-related diarrhea (CTD) in humans: The pivotal OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy, with or without chemotherapy, was initiated in October 2020 and is ongoing. The trial is evaluating the effectiveness of crofelemer's novel mechanism of action – the modulation of two chloride ion channels in the gastrointestinal tract – to mitigate or substantially reduce chronic cancer therapy-related diarrhea. Jaguar’s expectation is that this placebo-controlled trial will provide evidence that diarrhea associated with targeted cancer therapies is chronic, not acute, and impacts the patient's ability to remain on their cancer therapy regimens at proven doses for better outcomes. Each year, according to the CDC, more than 1 million cancer patients receive chemotherapy or radiation in an outpatient oncology clinic in the U.S. Treatment can last for months to years, in both the curative and metastatic situations. Crofelemer is currently approved for a chronic use in HIV/AIDS patients, providing a potential opportunity for a paradigm shift for prophylaxis of CTD compared to the management of severe chronic diarrhea with constipating agents such as antimotility drugs, which are predominantly opioids.
February 2023: FDA granted Orphan Drug Designation for crofelemer for Microvillus Inclusion Disease (MVID), a second rare disease indication: As announced, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to crofelemer for the indication of microvillus inclusion disease (MVID), a rare congenital diarrheal disorder (CDD), following review of the ODD application the Company submitted to the FDA. Crofelemer is a new molecular entity that now holds four orphan designations, as crofelemer previously received ODD for MVID from the European Medicines Agency (EMA) and for short bowel syndrome (SBS) from both the FDA and the EMA. Jaguar is planning to support investigator-initiated proof-of-concept studies of crofelemer in patients with SBS-IF or MVID, focused on obtaining proof-of-concept (POC) of reduction of requirements of parenteral support including parenteral nutrition and/or intravenous fluids, in 2023. SBS and CDD are the initial focus of Napo Therapeutics, the Italian corporation established by Jaguar in Milan, Italy in 2021 with a mission to expand crofelemer access in Europe for the treatment and management of orphan and rare disease indications. In accordance with the guidelines of specific European Union countries, publications of POC data from these trials could support early patient access to crofelemer for SBS-IF or MVID through programs in Europe, potentially in 2024. Early access programs are revenue generating, and reimbursable for participating patients.
Q2 2023 Milestone: Submit Investigational New Drug (IND) application to FDA for MVID: As announced, the Company intends to submit an IND application to FDA in the second quarter of 2023 for crofelemer for this ultra-rare CDD condition.
January 2023: Jaguar and Filament Health, with Funding from One Small Planet, Formed Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses: The focus of U.S.-based joint venture Magdalena Biosciences, Inc. is to develop novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (ADHD) in adults. The goal of the collaboration is to extend the botanical drug development capabilities of Jaguar and Filament in order to develop pharmaceutical-grade, standardized drug candidates for mental health disorders, and to partner with a potential future licensee to develop and commercialize these novel plant-based drugs.
September 2022: The Company announced activation by the FDA of IND application for NP-300, a novel drug candidate for the symptomatic relief and treatment of diarrhea from cholera and other pathogens: The Company plans to conduct a phase 1 trial in healthy volunteers, and following the completion of the phase 1 trial, the Company will be positioned to initiate the next stage of its clinical development program for cholera-related diarrhea when the Company’s development team has the requisite resources and bandwidth to initiate the additional required trials. The Company is grateful for the partial financial support from the National Institute of Allergy and Infectious Diseases (NIAID) to support the NP-300 preclinical program. NP-300 is a novel oral botanical drug product that is sustainably derived from the Croton lechleri tree, the same source as that for crofelemer, and is planned to be developed under the FDA's Botanical Guidance. As stated on the FDA's website, crofelemer is currently one of only two drugs that have been approved under the FDA's Botanical Guidance definition of a botanical drug product. Upon completion of the requisite development activities to support the New Drug Application (NDA) and subsequent approval of NP-300 by the FDA for the symptomatic relief and treatment of diarrhea from cholera, the Company intends to pursue a Tropical Disease Priority Review Voucher to develop NP-300 for this indication under the FDA's financial incentive program. Priority review vouchers are transferable, and in past transactions by other companies have sold for values ranging from $67 million to $350 million, which provides for a potential immediate return on investment upon approval of NP-300 for the cholera-related diarrhea indication.
Other investigator-initiated trials of crofelemer:
Currently ongoing: Study of chronic idiopathic diarrhea in non-HIV adult patients
Study Name: Yield of Diagnostic Tests and Management of Crofelemer for Chronic Idiopathic Diarrhea in Non-HIV Patients: A Pilot Study
Location: University of Texas Health Science Center at Houston
Currently ongoing: Study of functional diarrhea in non-HIV adult patients
Study Name: A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of crofelemer in subjects with functional diarrhea
Location: Beth Israel Deaconess Medical Center, a Harvard Medical School institution in Boston
COMPANY FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2022:
“As previously announced, the transition we completed in January 2022 to a limited distribution network of specialty pharmacies resulted in a meaningful reduction in Mytesi distribution costs as well as a higher average net price,” Ian Wendt, Jaguar's Chief Commercial Officer, stated. “I am very pleased to report that we significantly outperformed the industry gross-to-net average in the fourth quarter of 2022 – as we did in the four previous quarters – for sales of our human prescription product. This improvement in our gross-to-net was largely a result of the efficiencies realized by the transition to a closed network of specialty pharmacies. While Mytesi net revenue increased by 3.0% in the fourth quarter of 2022 over the third quarter of 2022, Mytesi total prescription volume decreased slightly by approximately 2% in this time period. This transition to specialty pharmacy distribution also assists in the preparation of the Company’s U.S. commercial distribution network for potential future indication expansion of crofelemer to other populations of patients with complex medical needs, such as CTD, inflammatory bowel disease, and SBS.”
The Company believes the availability of Mytesi through specialty pharmacies represents a significant benefit to patients, as such pharmacies focus on complex and chronic conditions and offer a higher level of support for prior authorizations, appeals, adherence reminders, counseling, and home delivery options.
Mytesi Prescription Volume: Mytesi total prescription volume was approximately 5,947 in the year 2022. Due to the transition to a limited distribution specialty pharmacy model in 2022, the Company cannot accurately compare prescription volume from 2021 to 2022, as there are significant differences in reporting methodology from these different distribution models. In the future, the Company will be able to accurately reflect growth in prescription volume using 2022 as the new baseline. Mytesi total prescription volume decreased slightly by approximately 2% in the fourth quarter of 2022 over the third quarter of 2022. Prescription volume differs from invoiced sales volume, which reflects, among other factors, varying buying patterns among specialty pharmacies in the closed network as they manage their inventory levels.
Net Mytesi Revenue: Net revenue for Mytesi was approximately $11.7 million in the year 2022, representing an increase of 174.8% over Mytesi net revenue in the year 2021, which totaled approximately $4.3 million. Mytesi net revenue was approximately $3.2 million in the fourth quarter of 2022, representing an increase of 3.0% over Mytesi net revenue in the third quarter of 2022, which totaled approximately $3.1 million, and an increase of approximately 55.8% over Mytesi net revenue in the fourth quarter of 2021, which totaled approximately $2.1 million.
The transition to a limited distribution network of specialty pharmacies, which was completed in January 2022, resulted in a meaningful reduction in Mytesi distribution costs and a higher average net price. As part of the process of transitioning to the closed specialty pharmacy network, the third and fourth quarters of 2021 were significantly impacted by the inventory draw-down of approximately 1,300 bottles of Mytesi across the Company’s third-party logistics warehouse, wholesalers, distributors, and retail stores.
Net Canalevia®-CA1 Revenue: Net revenue for the Company’s other crofelemer prescription product, Canalevia-CA1, which became commercially available in April 2022, was approximately $167 thousand in 2022. Canalevia-CA1 net revenue was approximately $24 thousand in the fourth quarter of 2022, representing an increase of 100% over Canalevia-CA1 net revenue in the third quarter of 2022, which totaled approximately $12 thousand.
Neonorm™: Revenues for the non-prescription Neonorm products were minimal for the fourth quarters of 2022 and 2021, in accordance with the Company’s primary focus on human health and prescription products.
Cost of Product Revenue: Total cost of product revenue for the year 2022 was $2.0 million compared to $2.3 million for the year 2021, representing a $0.3 million decrease year over year largely due to the reduction in distribution fees and decreased labor allocation in manufacturing.
Research and Development: The R&D expense increased by $2.6 million, from $15.1 million for the year 2021 to $17.7 million during the year 2022 largely due to increased clinical trial activities related to phase 3 CTD and other indications.
Sales and Marketing: The Sales and Marketing expense decreased slightly by $56 thousand from $8.9 million for the year 2021 to about the same in 2022. Direct marketing fees and expenses increased to expand market access to Mytesi through the Specialty Pharmacy channels but this was offset by the decrease in headcount.
General and Administrative: The G&A expense increased by $0.8 million, from $17.1 million for the year 2021 to $17.9 during the same quarter in 2022. The increase in expenses was largely due to an aggregate increase of $3.3 million in personnel and related benefits, public company expenses, rent, travel, and other expenses, offset by an aggregate decrease of $2.5 million in stock-based compensation, legal fees, consulting, and audit fees.
Loss from Operations: Loss from operations decreased by $6.3 million, from $40.7 million in the year 2021 to $34.4 million in 2022 largely due to the aggregate improvement in net revenue of $7.6 million, decreased cost of sales and marketing expenses of $0.4 million, and warrant inducement expenses of $1.6 million in 2021 and none recorded in 2022. These were offset by the aggregate increase in R&D and G&A expenses of $3.3 million.
Net Loss: Net loss attributable to common shareholders decreased by approximately $5.1 million, from $52.6 million in the year 2021 to $47.5 million in 2022. In addition to the loss from operations:
Interest expense increased by $4.3 million from $8.4 million in the year 2021 to $12.7 million in 2022 primarily due to additional interest expense incurred on royalty interest agreements primarily as result of the change in the timing of payments due to exchanges and a new royalty interest purchase agreement.
The loss on extinguishment of debt increased $1.4 million from $0.8 million for the year 2021 to $2.2 million in 2022 due to the extinguishment loss from the exchange of the outstanding balance of a royalty agreement for shares of the Company’s common stock.
Change in fair value of financial instrument and hybrid instrument designated at Fair Value Option (“FVO") decreased $1.9 million from a loss of approximately $2.0 million in the year 2021 to a loss of about $21,000 for the year 2022 primarily due to fair value adjustments in liability classified warrants and notes payable designated at FVO.
Other income (expenses) increased $1.7 million from approximately $0.8 million other expense for the year 2021 to approximately $1.0 million other income in 2022 due to write-off of extinguished liabilities as a result of legal release and reversal of long outstanding accruals with reasonable uncertainty to not be incurred.
Non-GAAP EBITDA: Non-GAAP EBITDA for the year 2022 and the year 2021 were a net loss of $28.1 million and net loss of $37.5 million, respectively.
Note Regarding Use of Non-GAAP Measures
The Company supplements its condensed consolidated financial statements presented on a GAAP basis by providing non-GAAP EBITDA and non-GAAP recurring EBITDA, which are considered non-GAAP under applicable SEC rules. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information that reflects the basis upon which Company management assesses and operates the business. These non-GAAP financial measures are not in accordance with GAAP and should not be viewed in isolation or as substitutes for GAAP net sales and GAAP net loss and are not substitutes for, or superior to, measures of financial performance in conformity with GAAP.
The Company defines non-GAAP EBITDA as net loss before interest expense and other expense, depreciation of property and equipment, amortization of intangible assets, share-based compensation expense and provision for or benefit from income taxes. The Company defines non-GAAP Recurring EBITDA as non-GAAP EBITDA adjusted for certain non-recurring revenues and expenses. Company management believes that non-GAAP EBITDA and non-GAAP Recurring EBITDA are meaningful indicators of Jaguar’s performance and provide useful information to investors regarding the Company’s results of operations and financial condition.
Participation Instructions for Webcast
When: Monday, March 27, 2023, at 8:00 AM Eastern Time
Participant Registration & Access Link: Click Here
Replay Instructions for Webcast
Replay of the webcast on the investor relations section of Jaguar’s website: (click here)
About Crofelemer
Crofelemer is the only oral FDA approved drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, Jaguar Health's wholly owned U.S. subsidiary, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities.
About Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics & Jaguar Animal Health
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, sustainably-derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Jaguar Health's wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human pharmaceuticals from plants harvested responsibly from rainforest areas. Our crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar Health is the majority shareholder of Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.), an Italian corporation established by Jaguar Health in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe. Jaguar Animal Health is a tradename of Jaguar Health.
For more information about Jaguar Health, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo Therapeutics, visit napotherapeutics.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the Company’s expectation that patient enrollment in the OnTarget trial will complete in Q2 2023, Jaguar’s expectation that the OnTarget trial will provide evidence that diarrhea associated with targeted cancer therapies is chronic, not acute, and impacts the patient's ability to remain on their cancer therapy regimens at proven doses for better outcomes, the Company’s expectation that crofelemer’s current approval for a chronic use in HIV/AIDS patients provides a potential opportunity for a paradigm shift for prophylaxis of CTD compared to the management of severe chronic diarrhea with constipating agents such as antimotility drugs, the expectation that Jaguar and Napo Therapeutics will support investigator-initiated proof-of-concept (POC) studies of crofelemer in 2023 for SBS with intestinal failure and congenital diarrheal disorders, the Company’s expectation that publications of data from these POC trials could support early patient access to crofelemer for SBS-IF or MVID through programs in Europe, potentially in 2024, the Company’s expectation that it will submit an IND application in Q2 2023 to FDA for crofelemer for MVID, the Company’s expectation that it will conduct a phase 1 trial of NP-300 in healthy volunteers, the Company’s expectation that NP-300 will be developed under the FDA's Botanical Guidance, the Company’s expectation that it will pursue a Tropical Disease Priority Review Voucher to develop NP-300, the Company’s expectation that it will in the future be able to accurately reflect growth in Mytesi prescription volume using 2022 as the new baseline, and the Company’s expectation that it will host an investor webcast on March 27, 2023. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Source: Jaguar Health, Inc.
Contact:
hello@jaguar.health
Jaguar-JAGX
QBAN: 0.0002
52w: 0.0002 – 0.0009
2 years: 0.0002 – 0.0018
https://www.telcocuba.com/
Telco Cuba, Inc. is a technology solutions service provider, which offers services under the brand name Amgentech and Telco Cuba. The Company offers telecommunication services and equipment, including mobile phones, mobile voice service, voice over Internet protocol (VoIP) service, and calling cards. The Company intends to offer prepaid service/plans that include predefined minute/unlimited minute plans. Under the brand name Telco Cuba, the Company is targeting the Cuban American demographic in the United States. Under the brand name Amgentech, the Company offers technology solutions, which include but are not limited to software and network architecture services, software development, Website development, hosting and colocation services, managed network and managed server services, voice over Internet protocol (IP) servers and bulk mailing services.
NO DILUTION
The company has authorized the issuance of 7,999,000,000 of which 7,259,394,066 have been issued as of 02/28/2023. Each common share is entitled to vote on all matters submitted to a vote of the holders of the company
7,259,394,066 as of 11/30/2022
7,259,394,066 as of 11/30/2021
7,259,394,066 as of 02/28/2021
Advanced Satellite Systems, Inc. provides Internet service in speed increments of 5, 25, 50, and 100MB/s.
VoIP telephone service is provided with unlimited calling to the US, Canada, and Mexico. Service to other
countries is metered at predefined rates. Cable television service is provided in increments of 25, 50, and 100
channels and forthcoming will be offered via an IPTV infrastructure offering basic service of 103 channels,
expanded service with an additional 35 channels, and premium channels offered on an a la cart basis.
Under the brand name “Amgentech”, the company offers best of breed technology solutions which include, but
are not limited to Software and Network architecture services, software development, web site development,
hosting and colocation services, managed network and managed server services, voice over ip servers and
bulk mailing services. Amgentech has been providing services since 2001, building out networks and services
in the international markets of Colombia, Costa Rica, and Panama.
Amgentech, Inc. is a Florida based Corporation engaged in the business of providing technology solutions,
integrating and building technology infrastructure and software and website development. Amgentech, Inc. also
offers managed collocated and leased servers. Originally founded in 2001, Amgentech, Inc. has been providing
Internet based solutions, VoIP infrastructure and consulting services for over 20 years to diverse clients in The
United States of America, the countries of Colombia, Costa Rica, El Salvador, Nicaragua, Panama, and
Venezuela. Amgentech, Inc. continues to provide these same services, in addition to providing the technical
and Internet know how to implement the technological vision that is envisioned for Solidus Communications,
Inc., Amgentech will be the sole technical services provider.
QBAN: 0.0002
52w: 0.0002 – 0.0009
2 years: 0.0002 – 0.0018
https://www.telcocuba.com/
Telco Cuba, Inc. is a technology solutions service provider, which offers services under the brand name Amgentech and Telco Cuba. The Company offers telecommunication services and equipment, including mobile phones, mobile voice service, voice over Internet protocol (VoIP) service, and calling cards. The Company intends to offer prepaid service/plans that include predefined minute/unlimited minute plans. Under the brand name Telco Cuba, the Company is targeting the Cuban American demographic in the United States. Under the brand name Amgentech, the Company offers technology solutions, which include but are not limited to software and network architecture services, software development, Website development, hosting and colocation services, managed network and managed server services, voice over Internet protocol (IP) servers and bulk mailing services.
NO DILUTION
The company has authorized the issuance of 7,999,000,000 of which 7,259,394,066 have been issued as of 02/28/2023. Each common share is entitled to vote on all matters submitted to a vote of the holders of the company
7,259,394,066 as of 11/30/2022
7,259,394,066 as of 11/30/2021
7,259,394,066 as of 02/28/2021
Advanced Satellite Systems, Inc. provides Internet service in speed increments of 5, 25, 50, and 100MB/s.
VoIP telephone service is provided with unlimited calling to the US, Canada, and Mexico. Service to other
countries is metered at predefined rates. Cable television service is provided in increments of 25, 50, and 100
channels and forthcoming will be offered via an IPTV infrastructure offering basic service of 103 channels,
expanded service with an additional 35 channels, and premium channels offered on an a la cart basis.
Under the brand name “Amgentech”, the company offers best of breed technology solutions which include, but
are not limited to Software and Network architecture services, software development, web site development,
hosting and colocation services, managed network and managed server services, voice over ip servers and
bulk mailing services. Amgentech has been providing services since 2001, building out networks and services
in the international markets of Colombia, Costa Rica, and Panama.
Amgentech, Inc. is a Florida based Corporation engaged in the business of providing technology solutions,
integrating and building technology infrastructure and software and website development. Amgentech, Inc. also
offers managed collocated and leased servers. Originally founded in 2001, Amgentech, Inc. has been providing
Internet based solutions, VoIP infrastructure and consulting services for over 20 years to diverse clients in The
United States of America, the countries of Colombia, Costa Rica, El Salvador, Nicaragua, Panama, and
Venezuela. Amgentech, Inc. continues to provide these same services, in addition to providing the technical
and Internet know how to implement the technological vision that is envisioned for Solidus Communications,
Inc., Amgentech will be the sole technical services provider.